CA3188286A1 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate and methods of synthesis - Google Patents

Abstract

The invention provides polymorphs of a compound of Formula (X). The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.

Description

CRYSTAL FORMS OF 244-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-Cross-Reference to Related Applications This application claims the benefit of, and priority to, U.S. Provisional Patent Application No. 63/046,120, filed June 30, 2020, and U.S. Provisional Patent Application No. 63/046,123, filed June 30, 2020, the contents of each of which are incorporated by reference.
Field of the Invention The invention relates to crystallographic forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate and method of chemical synthesis of that compound.
Background Heart disease is the leading cause of death worldwide, accounting for 15 million deaths across the globe in 2015. In many forms of heart disease, decreased cardiac efficiency stems from changes in mitochondrial energy metabolism. Mitochondria are sub-cellular compartments in which metabolites derived from glucose and fatty acids are oxidized to produce high-energy molecules. Increasing fatty acid oxidation in the heart decreases glucose oxidation, and vice versa. Glucose oxidation is a more efficient source of energy, but in certain types of heart disease, such as heart failure, ischemic heart disease, and diabetic cardiomyopathies, fatty acid oxidation predominates in cardiac mitochondria. As a result, the pumping capacity of the heart is reduced.
CV-8972, which has the IUPAC name 244-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate and the following structure:

CH
H-CO

I
N
1-13C0 ' was recently identified as a promising therapeutic candidate for treating or preventing cardiac conditions due to its pharmacokinetic profile.
Summary Provided herein are crystallographic forms of CV-8972 and compositions containing them. The invention recognizes that crystals of CV-8972 exist in multiple polymorphic forms and that one polymorph, Form A, is the most stable under conditions of ambient temperature and relative humidity. Therefore, Form A crystals of CV-8972 are useful for the manufacture of pharmaceutical compositions. For example, pharmaceutical compositions that contain the Form A polymorph do not require special handling during storage or distribution. In addition, such compositions may retain their efficacy better than compositions containing other polymorphs or mixtures of polymorphs. The invention also provides methods of treating cardiac conditions in subject using CV-8972 polymorphs, such as Form A.
The invention also provides methods of synthesis of CV-8972. Prior schemes for synthesis of CV-8972 require formation of a free base form of 2444(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanol, also called CV-8814, and conversion of the free base form of CV-8814 to a hydrochloride salt. In such schemes, CV-8814 must then be converted back to its free base form for coupling to nicotinic acid to form the free base form of CV-8972. The invention provides a CV-8972 synthesis scheme that bypasses the reversible conversion of CV-8814 between the free base and HC1 salt forms. In the schemes provided herein, the free base form of CV-8814 is formed in a reductive amination reaction, and the free base product is used directly as a substrate for coupling to nicotinic acid to form CV-8972.
Because fewer steps are required, the synthesis schemes of the invention are simpler, faster, and provide better yields than prior methods of making CV-8972.

2 In an aspect, the invention provides crystals comprising a polymorph of a compound of Formula (X):

H,C0 is, Kt It, ii3co 'N' 00.
The polymorph may be Form A, Form B, Form C, Form D, or Form E.
The crystal may be substantially free of one or more other polymorphs. For example, the crystal may include a Form A polymorph and be substantially free of polymorphs of Form B, Form C, Form D, and Form E.
The crystal may include a hydrochloride salt of the compound of Formula (X).
The crystal may include the compound of Formula (X) and the hydrochloride ion in a defined stoichiometric ratio. The crystal may include the compound and the hydrochloride ion in a 1:3 stoichiometric ratio.
The crystal may include a hydrated form of the compound of Formula (X). The crystal may include a monohydrate form of the compound. The crystal may include an anhydrous form of the compound.
In another aspect, the invention provides pharmaceutical compositions that include a polymorph of the compound of Formula (X).
The polymorph may be Form A, Form B, Form C, Form D, or Form E.
The composition may be substantially free of one or more other polymorphs. For example, the composition may include a Form A polymorph and be substantially free of polymorphs of Form B, Form C, Form D, and Form E.
The composition may include a hydrochloride salt of the compound of Formula (X). The composition may include the compound of Formula (X) and the hydrochloride ion in a defined stoichiometric ratio. The composition may include the compound and the hydrochloride ion in a 1:3 stoichiometric ratio.

3 The composition may include a hydrated form of the compound of Formula (X).
The composition may include a monohydrate form of the compound. The composition may include an anhydrous form of the compound.
The composition may be formulated for any route or mode of administration. The composition may be formulated for buccal, dermal, enteral, intraarterial, intramuscular, intraocular, intravenous, nasal, oral, parenteral, pulmonary, rectal, subcutaneous, topical, or transdermal administration. The composition may be formulated for administration by injection or with or on an implantable medical device (e.g., stent or drug-eluting stent or balloon equivalents).
The composition may be formulated as a single unit dosage. The composition may be formulated as divided dosages.
The composition may contain a defined dose of the compound. The dose may contain from about 10 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 10 mg to about 800 mg, from about 10 mg to about 600 mg, from about 10 mg to about 400 mg, from about 10 mg to about 300 mg, from about 10 mg to about 200 mg, from about 25 mg to about 2000 mg, from about 25 mg to about 1000 mg, from about 25 mg to about 800 mg, from about mg to about 600 mg, from about 25 mg to about 400 mg, from about 25 mg to about 300 mg, about 25 mg to about 200 mg, from about 50 mg to about 2000 mg, from about 50 mg to about 1000 mg, from about 50 mg to about 800 mg, from about 50 mg to about 600 mg, from about 50 20 mg to about 400 mg, from about 50 mg to about 300 mg, about 50 mg to about 200 mg, from about 100 mg to about 2000 mg, from about 100 mg to about 1000 mg, from about 100 mg to about 800 mg, from about 100 mg to about 600 mg, from about 100 mg to about 400 mg, from about 100 mg to about 300 mg, about 100 mg to about 200 mg, from about 200 mg to about 2000 mg, from about 200 mg to about 1000 mg, from about 200 mg to about 800 mg, from about 200 25 mg to about 600 mg, from about 200 mg to about 400 mg, from about 200 mg to about 300 mg, from about 300 mg to about 2000 mg, from about 300 mg to about 1000 mg, from about 300 mg to about 800 mg, from about 300 mg to about 600 mg, or from about 300 mg to about 400 mg of the compound. The dose may contain about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg of the compound.
The composition may contain a crystal of the compound of Formula (X). The crystal may have any of the properties described above in relation to crystals of the compound.

4 In another aspect, the invention provides methods of treating a condition in a subject by providing to a subject having, or at risk of developing, a condition a composition containing a therapeutically effective amount of a polymorph of a compound of Formula (X).
The polymorph may be Form A, Form B, Form C, Form D, or Form E.
The composition may have any of the properties described above in relation to compositions that include the compound of Formula (X), including crystals of the compound.
The composition may be provided by any suitable route or mode of administration. The composition may be provided buccally, dermally, enterally, intraarterially, intramuscularly, intraocularly, intravenously, nasally, orally, parenterally, pulmonarily, rectally, subcutaneously, topically, transdermally, by injection, or with or on an implantable medical device (e.g., stent or drug-eluting stent or balloon equivalents).
The composition may be provided as a single unit dosage. The composition may be provided as divided dosages.
The composition may be provided in one dose per day. The composition may be provided in multiple doses per day. The composition may be provided in two, three, four, five, six, eight, or more doses per day.
The composition may contain a defined dose of the compound, such as any of the doses described above.
The dose or doses may be provided for a defined period. One or more doses may be provided daily for at least one week, at least two weeks, at least three weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least twelve weeks or more.
The condition may be a cardiovascular condition. The cardiovascular condition may be aneurysm, angina, atherosclerosis, cardiomyopathy, cerebral vascular disease, congenital heart disease, coronary artery disease, coronary heart disease, diabetic cardiomyopathy, heart attack, heart disease, heart failure, hypertension, ischemic heart disease, pericardial disease, peripheral arterial disease, rheumatic heart disease, stroke, transient ischemic attacks, or valvular heart disease. The angina may be refractory to other medical interventions.
The condition may be a rheumatic condition. The rheumatic condition may be acute kidney injury, alcoholic cardiomyopathy, angina (e.g., refractory angina and angina associated with heart failure), ankylosing spondylitis, autoimmune-related lung disease, Behcet's Disease, bursitis, cachexia, cardiac fibrosis, chemotherapy chronic fatigue syndrome, claudication (e.g.,

5 peripheral claudication), contrast nephropathy, cyanotic heart disease, dermatomyositis, dilated cardiomyopathy, disequilibrium, fibromyalgia, frailty, gout, Gulf War syndrome, heart failure, hypertrophic cardiomyopathy, induced nephropathy, infectious arthritis, inflammatory arthritis, inflammatory eye disease, inflammatory myositis, ischemic cardiomyopathy, juvenile idiopathic arthritis, left ventricular dysfunction, lupus, muscle myopathy, myofascial pain syndrome, myositis, osteoarthritis, osteonecrosis of the jaw, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, pulmonary arterial hypertension, pulmonary fibrosis, a rare muscle disease, rheumatoid arthritis, sarcoidosis, sarcopenia, scleroderma, Sjogren's syndrome, tendinitis, tinnitus, vasculitis, or vertigo.
The condition may fibrosis. The fibrosis may be associated with another disease, disorder, or condition. For example, the fibrosis may include or be associated with adhesive capsulitis, aneurysm, angina, arterial stiffness, arthrofibrosis, atherosclerosis, atrial fibrosis, cardiomyopathy, cerebral vascular disease, cirrhosis, congenital heart disease. coronary artery disease, coronary heart disease, Crohn's disease, cystic fibrosis, diabetic cardiomyopathy, Dupuytren's contracture, endomyocardial fibrosis, glial scar, heart attack, heart failure, high blood pressure (hypertension), idiopathic pulmonary fibrosis, ischemic heart disease, keloid, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, old myocardial infarction, pericardial disease, peripheral arterial disease, Peyronie's disease, progressive massive fibrosis, pulmonary fibrosis, radiation-induced lung injury, retroperitoneal fibrosis, rheumatic heart disease, scleroderma, stroke, systemic sclerosis transient ischemic attacks, or valvular heart disease.
The condition may be cancer. The cancer may be bladder cancer, brain cancer, breast cancer, carcinoma, cervical cancer, colon cancer, colorectal cancer, gastric cancer, glioblastoma, glioma, head and neck cancer, kidney cancer, leukemia, liposarcoma, liver cancer, lung cancer, lymphoma, medullablastoma, melanoma, muscle cancer, neuroblastoma, oligoastrocytoma, oligodendroglioma, osteosarcoma, ovarian cancer, pancreatic cancer, paraganglioma, prostate cancer, sarcoma, or thyroid cancer.
In another aspect, the invention provides methods of altering cardiac remodeling by providing to a subject that has developed, or is at risk of developing, cardiac remodeling a composition containing a therapeutically effective amount of a polymorph of a compound of Formula (X).

6 The polymorph may be Form A, Form B, Form C, Form D, or Form E.
The composition may have any of the properties described above in relation to compositions that include the compound of Formula (X), including crystals of the compound.
The composition may be provided by any suitable route or mode of administration. The composition may be provided buccally, dermally, enterally, intraocular intravenously, nasally, orally, parenterally, pulmonarily, subcutaneously, topically, transdermally, by injection, or with or on an implantable medical device (e.g., stent or drug-eluting stent or balloon equivalents).
The composition may be provided as a single unit dosage. The composition may be provided as divided dosages.
The composition may be provided in one dose per day. The composition may be provided in multiple doses per day. The composition may be provided in two, three, four, five, six, eight, or more doses per day.
The composition may contain a defined dose of the compound, such as any of the doses described above.
The dose or doses may be provided for a defined period. One or more doses may be provided daily for at least one week, at least two weeks, at least three weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least twelve weeks or more.
The cardiac remodeling may be associated with a disease, disorder, or condition. The cardiac remodeling may be associated with a cardiovascular disease. For example, the cardiac remodeling may be associated with aberrant subclavian artery, aortic regurgitation, aortic stenosis, arteriovenous malformation and fistula, atrial septal defect, atrioventricular septal defect, bicuspid aortic valve, cardiomegaly, cardiomyopathy, coarctation of the aorta, complete heart block, concentric hypertrophy, congenital heart defects, congenital heart disease, coronary artery disease, dextrocardia, dextro-transposition of the great arteries, diabetes, diet, double aortic arch, double inlet left ventricle, double outlet right ventricle, Ebstein's anomaly, giant hepatic hemangioma, heart failure, high cholesterol, high-output hemodialysis fistula, hypertension, hypertension, hypoplastic left heart syndrome, hypoplastic right heart syndrome, interrupted aortic arch, levo-transposition of the great arteries, mitral regurgitation, also causing left atrial volume overload, mitral stenosis, myocardial ischemia, obesity, outflow obstruction., partial anomalous pulmonary venous connection, patent ductus arteriosus, pentalogy of Cantrell, persistent truncus arteriosus, pressure overload, pulmonary atresia, pulmonary hypertension,

7

8 pulmonary regurgitation, pulmonary stenosis, rhabdomyomas, right ventricular volume overload, scimitar syndrome, Shone's syndrome, tetralogy of Fallot, total anomalous pulmonary venous connection, transposition of the great vessels, tricuspid atresia, tricuspid regurgitation, use of tobacco, alcohol, or other drugs, valvular heart disease, ventricular dilation, ventricular hypertrophy, ventricular septal defect, volume overload, and Wolff-Parkinson-White syndrome.
In another aspect, the invention provides uses of crystals containing a polymorph of a compound of Formula (X) for making a medicament.
In embodiments of the use, the polymorph is Form A, Form B, Form C, Form D, or Form E.
In embodiments of the use, the crystal is substantially free of one or more other polymorphs. In embodiments of the use, the crystal includes a Form A polymorph and is substantially free of polymorphs of Form B, Form C, Form D, and Form E.
In embodiments of the use, the crystal includes a hydrochloride salt of the compound of Formula (X). In embodiments of the use, the crystal includes the compound of Formula (X) and the chloride ion in a defined stoichiometric ratio. In embodiments of the use, the crystal includes the compound and the chloride ion in a 1:3 stoichiometric ratio.
In embodiments of the use, the medicament includes a hydrated form of the compound of Formula (X). In embodiments of the use, the medicament includes a monohydrate form of the compound. In embodiments of the use, the medicament includes an anhydrous form of the compound.
In embodiments of the use, the medicament is formulated for buccal, dermal, enteral, intraarterial, intramuscular, intraocular, intravenous, nasal, oral, parenteral, pulmonary, rectal, subcutaneous, topical, or transdermal administration. In embodiments of the use, the medicament is formulated for administration by injection or with or on an implantable medical device (e.g., stent or drug-eluting stent or balloon equivalents).
In embodiments of the use, the medicament is formulated as a single unit dosage. In embodiments of the use, the medicament is formulated as divided dosages.
In embodiments of the use, the medicament contains from about 10 mg to about mg, from about 10 mg to about 1000 mg, from about 10 mg to about 800 mg, from about 10 mg to about 600 mg, from about 10 mg to about 400 mg, from about 10 mg to about 300 mg, from about 10 mg to about 200 mg, from about 25 mg to about 2000 mg, from about 25 mg to about 1000 mg, from about 25 mg to about 800 mg, from about 25 mg to about 600 mg, from about 25 mg to about 400 mg, from about 25 mg to about 300 mg, about 25 mg to about 200 mg, from about 50 mg to about 2000 mg, from about 50 mg to about 1000 mg, from about 50 mg to about 800 mg, from about 50 mg to about 600 mg, from about 50 mg to about 400 mg, from about 50 mg to about 300 mg, about 50 mg to about 200 mg, from about 100 mg to about 2000 mg, from about 100 mg to about 1000 mg, from about 100 mg to about 800 mg, from about 100 mg to about 600 mg, from about 100 mg to about 400 mg, from about 100 mg to about 300 mg, about 100 mg to about 200 mg, from about 200 mg to about 2000 mg, from about 200 mg to about 1000 mg, from about 200 mg to about 800 mg, from about 200 mg to about 600 mg, from about 200 mg to about 400 mg, from about 200 mg to about 300 mg, from about 300 mg to about 2000 mg, from about 300 mg to about 1000 mg, from about 300 mg to about 800 mg, from about 300 mg to about 600 mg, or from about 300 mg to about 400 mg of the compound. In embodiments of the use, the medicament contains about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg of the compound.
In another aspect, the invention provides methods for preparing a compound of Formula (X):

'1 3 HCO

'N' (X), by performing the steps of:
reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol to produce a free base form of a compound of Formula (IX):

9 OC HI
Nif. .

N ,---------,, .,--7' 1-18C0' (Do; and reacting the free base form of the compound of Formula (IX) with nicotinic acid to produce the compound of Formula (X), wherein the method does not comprise producing a salt form of the compound of Formula (IX).
The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may include one or more solvents, catalysts, or other chemicals. The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may include one or more of sodium triacetoxyborohydride, acetic acid, and 2-methyltetrahydrofuran.
The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may be performed at a defined temperature. The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may be performed at from about 10 C to about 30 C, from about C to about 30 C, from about 20 C to about 30 C, from about 25 C to about 30 C, from about

10 C to about 25 C, from about 15 C to about 25 C, from about 20 C to about 25 C, from about 15 10 C to about 20 C, or from about 15 C to about 20 C.
The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may not include a specific solvent, catalyst, or other chemical. The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-ypethan-1-ol may not include dichloromethane.
The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may produce a free base form of the compound of Formula (X).
The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may include one or more solvents, catalysts, or other chemicals. The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may include one or more of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 4-(dimethylamino)pyridine, and dichloromethane.

The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may be performed at a defined temperature. The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may be performed at from about 15 C to about 30 C, from about 20 C to about 30 C, from about 25 C to about 30 C, from about 15 C to about 25 C, from about 20 C to about 25 C, or from about 15 C to about 20 C.
The method may include converting the free base form of the compound of Formula (X) to a salt form of the compound of Formula (X). The salt form of the compound of Formula (X) may be a HC1 salt. The salt form of the compound of Formula (X) may be monohydrate.
The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may include one or more solvents, catalysts, or other chemicals. The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may include one or more of HC1 and methyl ethyl ketone.
The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may be performed at a defined temperature.
The step of .. converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may be performed at from about 40 C to about 60 C, from about 45 C to about 60 C, from about 50 C to about 60 C, from about 55 C to about 60 C, from about 40 C to about 55 C, from about 45 C to about 55 C, from about 50 C to about 55 C, from about 40 C to about 50 C, from about 45 C to about 50 C, from about 40 C to about 50 C, about 40 C, about 45 C, about 50 C, about 55 C, or about 60 C.
The method may include converting the salt form of the compound of Formula (X) from a first crystal form to a second crystal form. Each of the first and second crystal forms may independently be Form A, Form B, Form C, Form D, or Form E.
The step of converting the salt form of the compound of Formula (X) from a first crystal form to a second crystal form may include one or more of changing the solvent of the salt form of the compound of Formula (X) and incubating the salt form of the compound of Formula (X), at about 60 C.
The method may be performed without the use of one or more solvents, catalysts, or other chemicals. The method may be performed without the use of one or more of dioxane, ethylacetate, or potassium carbonate.

11 The method may include purifying the free base form of the compound of Formula (IX) The method may include crystallizing the free base form of the compound of Formula (IX).
In another aspect, the invention provides methods of preparing a compound of Formula (X) by performing the steps of:
reacting a compound of Formula (1):
µN-0 (1) with a compound of Formula (2):
H N

(2) to produce a free base form of a compound of Formula (IX):

H C
N
= N
H OH
CO
(IX);
reacting the free base form of a compound of Formula (IX) with a compound of Formula (3):

12 (3) to produce a free base form of the compound of Formula (X); and converting the free base form of the compound of Formula (X) to a HC1 salt of the compound of Formula (X), wherein the method does not comprise producing a salt form of the compound of Formula (IX).
The method may include purifying the free base form of the compound of Formula (IX).
The method may include crystallizing the free base form of the compound of Formula (IX).
Brief Description of the Drawings FIG. 1 is a space-filling three-dimensional model of the crystal structure of the Form D
polymorph of CV-8972.
FIG. 2 is a space-filling three-dimensional model of the crystal structure of the Form D
polymorph of CV-8972 at room temperature.
FIG. 3 is a space-filling three-dimensional model of the crystal structure of the Form A
polymorph of CV-8972.
FIG. 4 is an XRPD diffractogram of the CV-8972 starting material.
FIG. 5 shows TGA and DSC thermograms of the CV-8972 starting material.
FIG. 6 shows XRPD diffractograms of various forms of CV-8972.
FIG. 7 is a polarized microscopic image of CV-8972 starting material.
FIG. 8 is a dynamic vapor sorption isotherm plot.
FIG. 9 shows XRPD diffractograms of CV-8972 before and after dynamic vapor sorption.
FIG. 10 shows XRPD diffractograms of CV-8972 in its dehydrated and rehydrated forms.
FIG. 11 shows XRPD diffractograms of various polymorphs of CV-8972.

13 FIG. 12 is a PLM image of a batch of single crystals of C22H34C13N306 (CV-8972).
FIG. 13 shows PLM images of a crystal used for single-crystal diffractometer.
FIG. 14 shows images of a crystal mounted on a 100 micro Mitegen loop on the diffractometer.
FIG. 15 is an Ortep diagram of an asymmetric unit of the C22H34C13N306 crystal.
FIG. 16 shows one unit cell of the C22H34C13N306 crystal.
FIG. 17 is a diagram of hydrogen bonds networks and counter-ion pairs in the C22H34C13N306 crystal.
FIG. 18 shows calculated and measured XRPD diagrams of the C22H34C13N306 crystal.
FIG. 19 shows PLM images of single anhydrous crystals from recrystallized CV-8972.
FIG. 20 is an image of a single anhydrous crystal from recrystallized CV-8972 mounted on a tip of a glass fiber.
FIG. 21 is a thermal ellipsoid diagram of an asymmetric unit of the crystal.
FIG. 22 shows one unit cell of the C22H32C13N305 crystal.
FIG. 23 is a diagram of hydrogen bonds networks and counter-ion pairs in the C22H32C13N305 crystal.
FIG. 24 shows calculated and measured XRPD diagrams of the C22H34C13N306 crystal.
Detailed Description The recently-identified compound CV-8972 holds promise as a therapeutic agent for treating a variety of conditions, including cardiovascular conditions, rheumatic diseases, fibrosis, and cancer. CV-8972, which has the IUPAC name 2444(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate and the following structure:

14 OC F+, H3:00..,.õ-cõ.,.."N.,,,N,,, õ, N
113C0 ' 1 ,) , ,,,-L,,,11 is metabolized in the body into two sets of products that increase mitochondrial energy production in different ways. In an initial reaction, the molecule is split into CV-8814, which has the following structure:

Ø..
j , and nicotinic acid. Over time, CV-8814 converted in the body to trimetazidine.
Both CV-8814 .. and trimetazidine inhibit beta-oxidation of fatty acids and therefore shift mitochondrial metabolism toward oxidation of glucose, a more oxygen-efficient source of energy. Nicotinic acid serves as precursor for synthesis of nicotinamide adenine dinucleotide (NAD). NAD+
promotes mitochondrial respiration to drive ATP synthesis, regardless of whether glucose or fatty acids are used as the carbon source. Thus, the two sets of products that result from breakdown of CV-8972 in vivo act synergistically to stimulate energy production in mitochondria in cardiac tissue and other cell types. CV-8972 and its mechanism of action are described in U.S. Patent No. 10,556,013, the contents of which are incorporated herein by reference.
U.S. Patent No. 10,556,013 also provides a scheme for synthesis of CV-8972.
The scheme entails formation of a free base form of CV-8814 by reductive amination of 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-ypethan-1-ol. Due to the difficulty of isolating CV-8814 in a solid form in this prior method, the product of this reaction is then converted to a hydrochloride salt of CV-8814. However, CV-8814 must be converted back to its free base form for use in the esterification reaction with nicotinic acid that produces CV-8972.
The present invention recognizes that crystals of CV-8972 exist in multiple polymorphic forms. One polymorph, Form A, is most stable under conditions of ambient temperature and relative humidity and therefore has particular utility for the manufacture of pharmaceutical compositions. Due to the stability of Form A, compositions containing this polymorph can readily be stored and distributed without loss of therapeutic efficacy. Thus, the invention provides compositions containing polymorphs of crystalline CV-8972, methods of making such compositions, and methods of using them to treat various conditions in a subject.
Polymorphs of CV-8972 As described in the examples below, crystals of CV-8972 may exist in at least five polymorphic forms: Form A, Form B, Form C, Form D, and Form E. Form A is monohydrate, and Forms B, D, and E are anhydrous. Form C was not obtained in purified form, so its hydration state could not be determined.
Crystals may be formed as salts of CV-8972. For example, crystals may be formed as hydrochloride salts of CV-8972.
FIG. 1 is a space-filling three-dimensional model of the crystal structure of the Form D
polymorph of CV-8972. The polymorph is a trihydrochloride salt, and chloride ions are shown in green.
FIG. 2 is a space-filling three-dimensional model of the crystal structure of the Form D
polymorph of CV-8972 at room temperature. The polymorph is a trihydrochloride salt, and chloride ions are shown in green.
FIG. 3 is a space-filling three-dimensional model of the crystal structure of the Form A
polymorph of CV-8972. The polymorph is a trihydrochloride salt, and chloride ions are shown in green.
Pharmaceutical compositions The invention provides pharmaceutical compositions that contain crystals of a polymorph of CV-8972. For example, the composition may contain CV-8972 crystals in Form A, Form B, Form C, Form D, or Form E. The composition may be substantially free of one or more other polymorphs. For example, the composition may include a Form A polymorph and be substantially free of polymorphs of Form B, Form C, Form D, and Form E.
A composition containing a polymorph of CV-8972 may be substantially free of one or more other polymorphic forms of CV-8972 if the composition contains the predominant polymorph at a defined level of purity. Purity may be expressed as the amount of predominant polymorph as a percentage of the total weight of two of more polymorphs of CV-8972.
In certain embodiments, the total weight is the weight of all polymorphs of CV-8972 in the composition. For example, a composition that contains the Form A polymorph and is substantially free of other polymorphs may contain Form A at a defined weight percentage of all polymorphs of CV-8972 in the composition. For example, the composition may contain Form A
at at least 95% by weight, at least 96% by weight, at least 97% by weight, at least 98% by weight, at least 99% by weight, at least 99.5% by weight, at least 99.6% by weight, at least 99.7% by weight, at least 99.8% by weight, or at least 99.9% by weight of all polymorphs of CV-8972 in the composition.
In certain embodiments, the total weight is the weight of selected polymorphs of CV-8972 in the composition. For example, a composition that contains the Form A
polymorph and is substantially free of the Form B polymorph may contain Form A at a defined weight percentage of Forms A and B. For example, the composition may contain Form A
at at least 95% by weight, at least 96% by weight, at least 97% by weight, at least 98% by weight, at least 99% by weight, at least 99.5% by weight, at least 99.6% by weight, at least 99.7% by weight, at least 99.8% by weight, or at least 99.9% by weight of Forms A and B of CV-8972 in the composition. Similarly, a composition that contains the Form A polymorph and is substantially free of the Form B and C polymorphs may contain Form A at a defined weight percentage of Forms A, B, and C. For example, the composition may contain Form A at at least 95% by weight, at least 96% by weight, at least 97% by weight, at least 98% by weight, at least 99% by weight, at least 99.5% by weight, at least 99.6% by weight, at least 99.7% by weight, at least 99.8% by weight, or at least 99.9% by weight of Forms A, B, and C of CV-8972 in the composition.
Alternatively or additionally, a composition containing a polymorph of CV-8972 may be substantially free of one or more other polymorphic forms of CV-8972 if the composition contains the secondary polymorphs at levels below a defined level. Presence of a secondary polymorphs may be defined as the amount of one or more secondary polymorphs as a percentage of the total weight of two of more polymorphs of CV-8972.
In certain embodiments, the total weight is the weight of all polymorphs of CV-8972 in the composition. For example, a composition that contains the Form A polymorph and is substantially free of other polymorphs may contain all polymorphs other than Form A at a defined weight percentage of all polymorphs of CV-8972 in the composition. For example, the composition may contain all polymorphs other than Form A at below 5% by weight, below 4%
by weight, below 3% by weight, below 2% by weight, below 1% by weight, below 0.5% by weight, below 0.4% by weight, below 0.3% by weight, below 0.2% by weight, or below 0.1% by weight of all polymorphs of CV-8972 in the composition.
In certain embodiments, the total weight is the weight of selected polymorphs of CV-8972 in the composition. For example, a composition that contains the Form A
polymorph and is substantially free of the Form B polymorph may contain Form B at a defined weight percentage of Forms A and B. For example, the composition may contain Form B
at below 5%
by weight, below 4% by weight, below 3% by weight, below 2% by weight, below 1% by weight, below 0.5% by weight, below 0.4% by weight, below 0.3% by weight, below 0.2% by weight, or below 0.1% by weight of Forms A and B of CV-8972 in the composition. Similarly, a composition that contains the Form A polymorph and is substantially free of the Form B and Form C polymorphs may contain Forms B and C at a defined weight percentage of Forms A, B, and C. For example, the composition may contain Forms B and C at below 5% by weight, below 4% by weight, below 3% by weight, below 2% by weight, below 1% by weight, below 0.5% by weight, below 0.4% by weight, below 0.3% by weight, below 0.2% by weight, or below 0.1% by weight of Forms A, B, and C of CV-8972 in the composition.
The composition may include a hydrochloride salt of a CV-8972 polymorph. The composition may include CV-8972 and the chloride ion a defined stoichiometric ratio. The composition may include CV-8972 and the chloride ion in a 1:3 stoichiometric ratio.
The composition may include a hydrated form of CV-8972. The composition may include a monohydrate form of CV-8972, such as the Form A polymorph. The composition may include an anhydrous form of CV-8972, such as a Form B, Form D, or Form E
polymorph.

The composition may be formulated for any route or mode of administration. The composition may be formulated for buccal, dermal, enteral, intraarterial, intramuscular, intraocular, intravenous, nasal, oral, parenteral, pulmonary, rectal, subcutaneous, topical, or transdermal administration. The composition may be formulated for administration by injection or with or on an implantable medical device (e.g., stent or drug-eluting stent or balloon equivalents).
The composition may be formulated as a single unit dosage. The composition may be formulated as divided dosages.
The composition may contain a defined dose of CV-8972. The dose may contain from about 10 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 10 mg to about 800 mg, from about 10 mg to about 600 mg, from about 10 mg to about 400 mg, from about 10 mg to about 300 mg, from about 10 mg to about 200 mg, from about 25 mg to about 2000 mg, from about 25 mg to about 1000 mg, from about 25 mg to about 800 mg, from about 25 mg to about 600 mg, from about 25 mg to about 400 mg, from about 25 mg to about 300 mg, about 25 mg to about 200 mg, from about 50 mg to about 2000 mg, from about 50 mg to about 1000 mg, from about 50 mg to about 800 mg, from about 50 mg to about 600 mg, from about 50 mg to about 400 mg, from about 50 mg to about 300 mg, about 50 mg to about 200 mg, from about 100 mg to about 2000 mg, from about 100 mg to about 1000 mg, from about 100 mg to about 800 mg, from about 100 mg to about 600 mg, from about 100 mg to about 400 mg, from about 100 .. mg to about 300 mg, about 100 mg to about 200 mg, from about 200 mg to about 2000 mg, from about 200 mg to about 1000 mg, from about 200 mg to about 800 mg, from about 200 mg to about 600 mg, from about 200 mg to about 400 mg, from about 200 mg to about 300 mg, from about 300 mg to about 2000 mg, from about 300 mg to about 1000 mg, from about 300 mg to about 800 mg, from about 300 mg to about 600 mg, or from about 300 mg to about 400 mg of CV-8972. The dose may contain about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg of CV-8972.
A pharmaceutical composition containing a polymorph of CV-8972 may be in a form suitable for oral use, such as tablets, troches, lozenges, fast-melts, dispersible powders or granules, or capsules. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the polymorph in admixture with non-toxic pharmaceutically acceptable excipients. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid, or talc. Preparation and administration of pharmaceutical compositions is discussed in U.S. Patent No. 6,214,841 and U.S. Patent Publication No. 2003/0232877, the contents of each of which are incorporated by reference herein. Formulations for oral use may also be presented as hard gelatin capsules in which the compounds are mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin. The formulation may allow controlled release of the polymorph of CV-8972 in the gastrointestinal tract by encapsulating the polymorph in an enteric coating.
Dispersible powders and granules provide the compounds in admixture with a dispersing .. or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavoring and coloring agents, may also be present.
Pharmaceutical compositions may contain mixtures that include erodible polymers that promote swelling of the mixture in an aqueous environment. An erodible polymer is any .. polymer that breaks down inside the body within a physiologically relevant time frame. The erodible polymer may have other characteristics that promote the gradual release of the polymorphic form of CV-8972 from the mixture. For example and without limitation, the polymer may be one or more of the following: biocompatible, i.e., not harmful to living tissue;
hydrophilic; hygroscopic; tending to form a hydrogel.
Without wishing to be bound by theory, the polymer-containing mixtures may promote gradual release by one or more mechanisms. For example, swelling of the mixture by absorption of water may facilitate diffusion of the polymorphic form of CV-8972 from the mixture.
Degradation of the polymer may also allow the polymorphic form of CV-8972 to be released from the mixture. Osmotic pressure due the high concentration gradient of compound between the inside and outside of the mixture may also contribute to diffusion of the polymorphic form of CV-8972 from the mixture.

For example and without limitation, the polymer may be a cellulose derivative, a gelatin derivative, e.g., a cross-linked gelatin derivative, or a polyester derivative.
Derivatives of cellulose, is a linear chain 13(1-4) linked D-glucose units, include polymers that contain substitutions on one of more of the hydroxyl groups of each glucose unit.
Substituents may be organic or inorganic and are typically attached via ester or ether linkages.
Cellulose ester derivatives include carboxymethyl cellulose (CMC), e.g., sodium carboxymethyl cellulose, ethyl cellulose, ethyl hydroxyethyl cellulose, ethyl methyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), and methylcellulose. Cellulose ether derivatives include cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, cellulose propionate, cellulose sulfate, cellulose triacetate, and nitrocellulose. The use of cellulose-based polymers to form biodegradable hydrogels is known in the art and described in, for example, Sannino, et al., Biodegradable Cellulose-based Hydrogels: Design and Applications, Materials 2009, 2, 353-373;
doi:10.3390/ma2020353, the contents of which are incorporated herein by reference.
The mixture may contain multiple polymers or multiple polymeric forms of the same polymer. For example, HPMC polymeric forms may differ in a variety of physical properties, including viscosity, degree of methoxyl substitution, degree of hydroxypropoxyl substitution, or average molecule weight.
The viscosity of a HMPC polymeric form may be determined by testing under standard conditions, including the concentration of EIMPC in the solution and the temperature of the solution. For example and without limitation, the HPMC concentration may be 1%, 1.5%, 2%, 2.5%, or 3%. For example and without limitation, the temperature of the solution may be 15 C, 16 C, 17 C, 18 C, 19 C, 20 C, 21 C, 22 C, 23 C, 24 C, or 25 C.
A polymeric form of a cellulose derivative, such as HPMC, may have a defined viscosity.
For example and without limitation, a polymeric form of HPMC may have a viscosity of from about 2 cP to about 4 cP, from about 4 cP to about 6 cP, from about 5 cP to about 8 cP, from about 12 cP to about 18 cP, from about 40 cP to about 60 cP, from about 80 cP
to about 120 cP, from about 300 cP to about 500 cP, from about 1200 cP to about 2400 cP, from about 2500 cP to about 5000 cP, from about 9000 cP to about 18,000 cP, from about 12,000 cP to about 24,000 cP, from about 12,000 cP to about 24,000 cP, from about 75,000 cP to about 150,000 cP, at least about 2 cP at least about 4 cP at least about 5 cP at least about 12 cP at least about 40 cP at least about 80 cP at least about 300 cP at least about 1200 cP at least about 2500 cP at least about 9000 cP at least about 12,000 cP at least about 12,000 cP at least about 75,000 cP less than about 4 cP, less than about 6 cP, less than about 8 cP, less than about 18 cP, less than about 60 cP, less than about 120 cP, less than about 500 cP, less than about 2400 cP, less than about 5000 cP, less than about 18,000 cP, less than about 24,000 cP, less than about 24,000 cP, or less than about 150,000 cP for a 2% aqueous solution of the polymeric form at 20 C.
Polymeric forms of cellulose derivatives, such as HPMC, may vary in their degree of substitution of the glucose units. The degree of substitution may be expressed as a weight percentage of the substituent or as a molar ratio of substituent to glucose unit. For a cellulose derivative that has two different substituents, such as HPMC, the polymeric form may be described by the degree of substitution for each substituent.
Each polymeric form of HPMC may independently have a defined degree of methoxyl substitution. For example and without limitation, the degree of methoxyl substitution may be from about 19% to about 24%, from about 22% to about 24%, from about 27% to about 30%, from about 27% to about 30%, or from about 28% to about 32%.
Each polymeric form of HPMC may independently have a defined degree of hydroxypropoxyl substitution. For example and without limitation, the degree of hydroxypropoxyl substitution may be from about 4% to about 8%, from about 7%
to about 10%, from about 7% to about 12%, from about 8% to about 10%, from about 8% to about 11%, or from about 9% to about 12%.
Each polymeric form of HPMC may independently have a defined average molecular weight. The average molecular weight may be about 10 kDa, about 13 kDa, about 20 kDa, about 26 kDa, about 41 kDa, about 63 kDa, about 86 kDa, about 110 kDa, about 120 kDa, about 140 kDa, about 180 kDa, or about 220 kDa.
When multiple forms of a polymer, such as HPMC, are present, one or more polymeric forms may be present in a defined amount. For example and without limitation, a polymer, such as HPMC, may contain about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by weight of one polymeric form.

Pharmaceutical compositions may include modified-release formulations that contain one or more polymorphic forms of CV-8972. The formulations contain mixtures that include one or more polymorphic forms of CV-8972 and one or more erodible polymers that promote swelling of the mixture in an aqueous environment. The hygroscopic and erodible properties of the polymers may allow the mixture to form a hydrogel that slowly breaks down in the digestive tract of the subject. Consequently, the mixture promotes the steady release of the polymorphic form of CV-8972 and metabolic products thereof into circulation.
The mixture may contain a defined amount of the polymorphic form of CV-8972.
The mixture may contain at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% by weight of the polymorphic form of CV-8972.
The mixture may contain the polymorphic form of CV-8972 and the polymer in a defined weight ratio. For example and without limitation, the mixture may contain the polymorphic form of CV-8972 and the polymer in a weight ratio of about 1:5, about 1:4, about 1:3, about 1:2, about 1:1, about 3:2, about 2:1, about 3:1, about 4:1, about 5:1, from about 1:100 to about 100:1, from about 1:100 to about 50:1, from about 1:100 to about 20:1, from about 1:100 to about 10:1, from about 1:100 to about 5:1, from about 1:100 to about 2:1, from about 1:50 to about 100:1, from about 1:50 to about 50:1, from about 1:50 to about 20:1, from about 1:50 to about 10:1, from about 1:50 to about 5:1, from about 1:50 to about 2:1, from about 1:20 to about 100:1, from about 1:20 to about 50:1, from about 1:20 to about 20:1, from about 1:20 to about 10:1, from about 1:20 to about 5:1, from about 1:20 to about 2:1, from about 1:10 to about 100:1, from about 1:10 to about 50:1, from about 1:10 to about 20:1, from about 1:10 to about 10:1, from about 1:10 to about 5:1, from about 1:10 to about 2:1, from about 1:5 to about 100:1, from about 1:5 to about 50:1, from about 1:5 to about 20:1, from about 1:5 to about 10:1, from about 1:5 to about 5:1, from about 1:5 to about 2:1, from about 1:3 to about 100:1, from about 1:3 to about 50:1, from about 1:3 to about 20:1, from about 1:3 to about 10:1, from about 1:3 to about 5:1, or from about 1:3 to about 2:1.
The pharmaceutical composition may be formulated for a particular route of administration. The pharmaceutical may be formulated for oral, enteral, intravenous, or rectal administration.
The pharmaceutical composition may be formulated as a unit dosage containing a defined amount of the polymorphic form of CV-8972. The unit dosage may contain about 5 mg, about mg, about 20 mg, about 50 mg, about 100 mg, about 200 mg, about 500 mg, from about 5 mg to about 10 mg, from about 5 mg to about 20 mg, from about 5 mg to about 50 mg, from about 5 mg to about 100 mg, from about 5 mg to about 200 mg, from about 5 mg to about 500 mg, from about 10 mg to about 20 mg, from about 10 mg to about 50 mg, from about 10 mg to about 100 5 mg, from about 10 mg to about 200 mg, from about 10 mg to about 500 mg, from about 20 mg to about 50 mg, from about 20 mg to about 100 mg, from about 20 mg to about 200 mg, from about mg to about 500 mg, from about 50 mg to about 100 mg, from about 50 mg to about 200 mg, from about 50 mg to about 500 mg, from about 100 mg to about 200 mg, from about 100 mg to about 500 mg, or from about 200 mg to about 500 mg of the polymorphic form of CV-8972.
10 The pharmaceutical composition may be formulated such that it produces a defined value for one or more parameters, as described below in relation to methods of the invention. For example and without limitation, the parameter may be Cmax, the interval between administration and achieving Cmax, T1/27 or AUC.
Pharmaceutical compositions of the invention may contain excipients. For example and

15 without limitation, the composition may contain sweetening agents, flavoring agents, coloring agents, or preserving agents. The compositions may contain one or more of mannitol, starch, and magnesium stearate.
Providing a polymorph of CV-8972 to a subject 20 The invention provides methods of treating a condition in a subject by providing a polymorph of CV-8972. The polymorph may be Form A, Form B, Form C, Form D, or Form E.
The polymorph of CV-8972 may be provided in a pharmaceutical composition, as described above. In certain embodiments of the methods, only a polymorph of Form A is provided.
The polymorph of CV-8972 may be provided by any suitable route or mode of administration. For example and without limitation, the polymorph of CV-8972 may be provided buccally, dermally, enterally, intraarterially, intramuscularly, intraocularly, intravenously, nasally, orally, parenterally, pulmonarily, rectally, subcutaneously, topically, transdermally, by injection, or with or on an implantable medical device (e.g., stent or drug-eluting stent or balloon equivalents).
The polymorph of CV-8972 may be provided according to a dosing regimen. A
dosing regimen may include a dosage, a dosing frequency, or both.

Doses may be provided at any suitable interval. For example and without limitation, doses may be provided once per day, twice per day, three times per day, four times per day, five times per day, six times per day, eight times per day, once every 48 hours, once every 36 hours, once every 24 hours, once every 12 hours, once every 8 hours, once every 6 hours, once every 4 hours, once every 3 hours, once every two days, once every three days, once every four days, once every five days, once every week, twice per week, three times per week, four times per week, or five times per week.
The dose may contain a defined amount of CV-8972 that improves cardiac mitochondrial function, such as any of the doses described above in relation to pharmaceutical compositions containing a polymorph of CV-8972.
The dose may be provided in a single dosage, i.e., the dose may be provided as a single tablet, capsule, pill, etc. Alternatively, the dose may be provided in a divided dosage, i.e., the dose may be provided as multiple tablets, capsules, pills, etc.
The dosing may continue for a defined period. For example and without limitation, doses .. may be provided for at least one week, at least two weeks, at least three weeks, at least four weeks, at least six weeks, at least eight weeks, at least ten weeks, at least twelve weeks or more.
The subject may be a human. The subject may be a human that has a cardiovascular condition, rheumatic condition, fibrosis, or cancer. The subject may be a human that is at risk of developing a cardiovascular condition, rheumatic condition, fibrosis, or cancer. A subject may .. be at risk of developing a condition if the subject does not meet established criteria for diagnosis of the condition but has one or more symptoms, markers, or other factors that indicate the subject is likely to meet the diagnostic criteria for the condition in the future. The subject may be a pediatric, a newborn, a neonate, an infant, a child, an adolescent, a pre-teen, a teenager, an adult, or an elderly subject. The subject may be in critical care, intensive care, neonatal intensive care, .. pediatric intensive care, coronary care, cardiothoracic care, surgical intensive care, medical intensive care, long-term intensive care, an operating room, an ambulance, a field hospital, or an out-of-hospital field setting.

Conditions that may be treated with a polymorph of CV-8972 The invention provides methods of treating a condition in a subject by providing a polymorph of CV-8972. The condition may be any disease, disorder, or condition for which increasing mitochondrial energy production provides a therapeutic benefit.
The condition may be a cardiac condition. For example and without limitation, the cardiac condition may be aneurysm, angina, atherosclerosis, cardiomyopathy, cerebral vascular disease, congenital heart disease, coronary artery disease (CAD), coronary heart disease, diabetic cardiomyopathy, heart attack, heart disease, heart failure, high blood pressure (hypertension), ischemic heart disease, pericardial disease, peripheral arterial disease, refractory angina, rheumatic heart disease, stable angina, stroke, transient ischemic attack, unstable angina, or valvular heart disease.
Angina pectoris (angina) is chest pain or pressure that is typically due to insufficient blood flow to the heart muscle. The pain or discomfort is retrosternal or left-sided and may radiate to the left arm, neck, jaw, or back. Several classifications of angina are known.
Stable angina, also called effort angina, is related to myocardial ischemia.
In stable angina, chest discomfort and associated symptoms are usually triggered by some physical activity, such as running or walking, but symptoms are minimal or non-existent when the patient is at rest or has taken sublingual nitroglycerin. Symptoms typically abate several minutes after activity and recur when activity resumes. Symptoms may also be induced by cold weather, heavy meals, and emotional stress.
Unstable angina is angina that changes or worsens. Unstable angina has at least one of the following features: (1) it occurs at rest or with minimal exertion, usually lasting more than 10 minutes, (2) it is severe and of new onset, i.e., within the prior 4-6 weeks, and (3) it occurs with a crescendo pattern, i.e., distinctly more severe, prolonged, or frequent than before.
Cardiac syndrome X, also called microvascular angina, is angina-like chest pain, in the context of normal epicardial coronary arteries on angiography. Its primary cause is unknown, but factors apparently involved are endothelial dysfunction and reduced flow in the tiny resistance blood vessels of the heart. Microvascular angina may be part of the pathophysiology of ischemic heart disease.
Refractory angina is a chronic condition (> 3 months in duration) in which angina (1) occurs in the context of coronary artery disease (CAD), (2) cannot be controlled by a combination of optimal medical therapy, angioplasty, or bypass surgery, and (3) in which reversible myocardial ischemia has been clinically established to be the cause of the symptoms.
Providing a polymorph of CV-8972 may improve cardiac efficiency in the subject. A
variety of definitions of cardiac efficiency exist in the medical literature.
See, e.g., Schipke, J.D.
.. Cardiac efficiency, Basic Res. Cardiol. 89:207-40 (1994); and Gibbs, C.L.
and Barclay, C.J.
Cardiac efficiency, Cardiovasc. Res. 30:627-634 (1995), incorporated herein by reference. One definition of cardiac mechanical efficiency is the ratio of external cardiac power to cardiac energy expenditure by the left ventricle. See Lopaschuk G.D., et al., Myocardial Fatty Acid Metabolism in Health and Disease, Phys. Rev. 90:207-258 (2010), incorporated herein by reference. Another definition is the ratio between stroke work and oxygen consumption, which ranges from 20-25% in the normal human heart. Visser, F., Measuring cardiac efficiency: is it useful? Hear Metab. 39:3-4 (2008), incorporated herein by reference. Another definition is the ratio of the stroke volume to mean arterial blood pressure. Any suitable definition of cardiac efficiency may be used to measure the effects of compounds of the invention A polymorph of CV-8972 may be used to treat a rheumatic disease, disorder, or condition. As used herein, a rheumatic disease, disorder, or condition is any condition that affects the joints, tendons, ligaments, bones, muscles, or connective tissue or is associated with pain in or more of such tissues. The rheumatic disease, disorder, or condition may primarily affect the joints, tendons, ligaments, bones, muscles, or connective tissue.
Examples of such conditions include ankylosing spondylitis, autoimmune-related lung disease, Behcet's Disease, bursitis, chronic fatigue syndrome, dermatomyositis, fibromyalgia, gout, Gulf War syndrome, infectious arthritis, inflammatory arthritis, inflammatory eye disease, inflammatory myositis, juvenile idiopathic arthritis, lupus, myofascial pain syndrome, osteoarthritis, osteonecrosis of the jaw, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, rheumatoid arthritis, .. sarcoidosis, scleroderma, Sjogren's syndrome, tendinitis, and vasculitis.
The rheumatic disease, disorder, or condition may primarily affect the cardiovascular system and have secondary effects on the joints, tendons, ligaments, bones, muscles, or connective tissue. For example and without limitation, the condition may be alcoholic cardiomyopathy, aneurysm, angina (including refractory angina and angina in the context of heart failure), atherosclerosis, cardiac fibrosis, cardiomyopathy, cerebral vascular disease, claudication (e.g., peripheral claudication) congenital heart disease, coronary artery disease, coronary heart disease, cyanotic heart disease, diabetic cardiomyopathy, dilated cardiomyopathy, heart attack, heart failure, high blood pressure (hypertension), hypertrophic cardiomyopathy, ischemic cardiomyopathy, ischemic heart disease, left ventricular dysfunction, pericardial disease, peripheral arterial disease, rheumatic heart disease, stroke, transient ischemic attacks, or valvular heart disease.
The rheumatic disease, disorder, or condition may be a rare muscle disease.
For example and without limitation, the condition may be CAV3-related distal myopathy, Duchenne Muscular Dystrophy, hypertrophic cardiomyopathy, isolated hyperCKemia, limb-girdle muscular dystrophy 1C, muscle myopathy, myositis, or rippling muscle disease. The rare muscle disease may be associated with a mutation in BICD2, CAV3, or DMD.
The rheumatic disease, disorder, or condition may be a glycogen storage disease. For example and without limitation, the glycogen storage disease may be aldolase A
deficiency, Andersen disease, Con's disease, Fanconi-Bickel syndrome, Hers' disease, Lafora disease, McArdle disease, Pompe's disease, Tarui's disease, or von Gierke's disease.
The glycogen storage disease may be associated with a deficiency in an enzyme or protein, such as acid alpha-glucosidase, aldolase A, P-enolase, glucose transporter, glucose-6-phosphatase, glycogen branching enzyme, glycogen debranching enzyme, glycogen synthase, glycogenin-1, liver glycogen phosphorylase, muscle glycogen phosphorylase, muscle lactate dehydrogenase, muscle phosphofructokinase, muscle phosphoglycerate mutase, phosphoglycerate mutase, or phosphorylase kinase. The glycogen storage disease may be associated with a mutation in a gene, such as AGL, ALDOA, EN03, G6PC, GAA, GBE1, GLUT2, GYG1, GYS2, LDHA, PGAM2, PGAM2, PHKA1, PHKA2, PHKB, PHKG2, PKFM, PYGL, PYGM, or SLC37A4.
The rheumatic disease, disorder, or condition may be another condition that affects the joints, tendons, ligaments, bones, muscles, or connective tissue, such as acute kidney injury, cachexia, chemotherapy induced nephropathy, contrast nephropathy, disequilibrium, frailty, pulmonary arterial hypertension, pulmonary fibrosis, sarcopenia, tinnitus, or vertigo.
A polymorph of CV-8972 may be used to treat fibrosis or a disease, disorder, or condition associated with fibrosis. In particular, the methods are useful for treating diseases, disorders, or conditions in which fibrosis in an organ or tissue is associated with reduced energy production by that organ or tissue. The fibrosis may affect any organ or tissue, such as the heart, lungs, liver, brain, cardiovascular system, joints, gastrointestinal system, limbs, digits, skin, bone marrow, or penis.
The fibrosis may be associated with another condition, e.g., it may be secondary to another condition, or it may lead to the other condition. For example and without limitation, the fibrosis may include or be associated with adhesive capsulitis, aneurysm, angina, arterial stiffness, arthrofibrosis, atherosclerosis, atrial fibrosis, cardiomyopathy, cerebral vascular disease, cirrhosis, congenital heart disease, coronary artery disease, coronary heart disease, Crohn's disease, cystic fibrosis, diabetic cardiomyopathy, Dupuytren's contracture, endomyocardial fibrosis, glial scar, heart attack, heart failure, high blood pressure (hypertension), idiopathic pulmonary fibrosis, ischemic heart disease, keloid, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, old myocardial infarction, pericardial disease, peripheral arterial disease, Peyronie's disease, progressive massive fibrosis, pulmonary fibrosis, radiation-induced lung injury, retroperitoneal fibrosis, rheumatic heart disease, scleroderma, stroke, systemic sclerosis transient ischemic attacks, or valvular heart disease.
A polymorph of CV-8972 may be used to treat cancer. For example and without limitation, the cancer may be bladder cancer, brain cancer, breast cancer, carcinoma, cervical cancer, colon cancer, colorectal cancer, gastric cancer, glioblastoma, glioma, head and neck cancer, kidney cancer, leukemia, liposarcoma, liver cancer, lung cancer, lymphoma, medullablastoma, melanoma, muscle cancer, neuroblastoma, oligoastrocytoma, oligodendroglioma, osteosarcoma, ovarian cancer, pancreatic cancer, paraganglioma, prostate cancer, sarcoma, or thyroid cancer.
Synthesis of CV-8972 The invention also provides CV-8972 synthesis schemes in which the free base form of CV-8814 formed as a product in the reductive amination reaction can be used directly as a substrate in the esterification reaction. The invention is based in part on the identification of conditions that improve the stability of CV-8814 free base and allow the free base form to be crystallized. Thus, the schemes provided herein obviate the need to convert CV-8814 from its free base form to a HCl salt and then back to the free base form.
Consequently, the invention provides simpler, quicker, and higher-yield methods for making CV-8972.
The invention provides methods for preparing a compound of Formula (X):

4CO, =1"\-3 -,^ ,- , ,,-"N., LT,,.
N

c0- - - .--- ------ -0- iii N-' N' (X), by performing the steps of:
reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol to produce a free base form of a compound of Formula (IX):
OHa -c--*-N

(IX); and \I
reacting the free base form of the compound of Formula (IX) with nicotinic acid to produce the compound of Formula (X), wherein the method does not comprise producing a salt form of the compound of Formula (IX).
2,3,4-trimethoxybenzaldehyde has the following structure:
N...., ,-J,,,,:r ......,....., -u --,,0----------:
.

2-(piperazin-1-yl)ethan-1-01 has the following structure:
HNF
=
Nicotinic acid has the following structure:

.,,,\ ..--""'"
I [ N's0H
N .
The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may include one or more solvents, catalysts, or other chemicals. The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may include one or more of sodium triacetoxyborohydride, acetic acid, and 2-methyltetrahydrofuran.
The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may be performed at a defined temperature. The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may be performed at from about 10 C to about 30 C, from about 15 C to about 30 C, from about 20 C to about 30 C, from about 25 C to about 30 C, from about 10 C to about 25 C, from about 15 C to about 25 C, from about 20 C to about 25 C, from about 10 C to about 20 C, or from about 15 C to about 20 C.
The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may not include a specific solvent, catalyst, or other chemical. The step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol may not include dichloromethane.
The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may produce a free base form of the compound of Formula (X).

The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may include one or more solvents, catalysts, or other chemicals. The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may include one or more of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 4-(dimethylamino)pyridine, and dichloromethane.
The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may be performed at a defined temperature. The step of reacting the free base form of the compound of Formula (IX) with nicotinic acid may be performed at from about 15 C to about 30 C, from about 20 C to about 30 C, from about 25 C to about 30 C, from about 15 C to about 25 C, from about 20 C to about 25 C, or from about 15 C to about 20 C.
The method may include converting the free base form of the compound of Formula (X) to a salt form of the compound of Formula (X). The salt form of the compound of Formula (X) may be a HC1 salt. The salt form of the compound of Formula (X) may be monohydrate.
The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may include one or more solvents, catalysts, or other chemicals. The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may include one or more of HC1 and methyl ethyl ketone.
The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may be performed at a defined temperature.
The step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) may be performed at from about 40 C to about 60 C, from about 45 C to about 60 C, from about 50 C to about 60 C, from about 55 C to about 60 C, from about 40 C to about 55 C, from about 45 C to about 55 C, from about 50 C to about 55 C, from about 40 C to about 50 C, from about 45 C to about 50 C, from about 40 C to about 50 C, about 40 C, about 45 C, about 50 C, about 55 C, or about 60 C.
The compound of Formula (X) may exist in at least five crystal forms: Form A, Form B, Form C, Form D, and Form E. Form A is monohydrate, and Forms B, D, and E are anhydrous.
The method may include converting the compound of Formula (X) from a first crystal form to a second crystal form. Each of the first and second crystal forms may independently be Form A, .. Form B, Form C, Form D, or Form E. The method may include one or more of the following conversions of the compound of Formula (X): from an anhydrous form to a hydrated form; from a hydrated form to an anhydrous form; from one anhydrous form to another; and from one hydrated form to another.
The step of converting the salt form of the compound of Formula (X) from a first crystal form to a second crystal form may include one or more of changing the solvent of the salt form of the compound of Formula (X) and incubating the salt form of the compound of Formula (X), at about 60 C.
The method may be performed without the use of one or more solvents, catalysts, or other chemicals. The method may be performed without the use of one or more of dioxane, ethylacetate, or potassium carbonate.
The method may include purifying the free base form of the compound of Formula (IX).
The method may include crystallizing the free base form of the compound of Formula (IX).
Examples Example 1 Summary A comprehensive polymorph screening for CV-8972, which has the structure of Formula (X), was undertaken. The CV-8972 starting material was characterized by X-ray powder diffraction (XRPD), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), dynamic vapor sorption (DVS), and polarized light microscopy (PLM). The data showed that the material is crystalline in nature and has similar XRPD pattern to that of the Form A. Starting with Form A, polymorph/single crystal screening experiments were set up under 34 conditions using methods of vapor diffusion, slow evaporation, and cooling crystallization. Five unique XRPD patterns were observed, which include Form A, Form B, Forms A + C, Form D, and Form E. Form A is monohydrate form as confirmed by single crystal structure.
Form D is anhydrous, and it was also confirmed by single crystal structure. Form E is an anhydrous form produced through dehydration of Form A at ¨90 C. Form B is a known anhydrate from a separate study. Form C was not obtained in the pure form during the study but rather appeared as a mixture of Forms A + C. Water activity analysis indicated that Form E
converts to Form A
under all conditions tested. In addition, when Form E was exposed to ambient temperature and humidity, it showed partial conversion to Form A. Further, the results from slurry competition between both anhydrous Forms D and E also indicated that both forms converted to Form A

during the experiments. These results suggest that the Form A is the most stable form at the ambient temperature and humidity.
Characterization of Form A
The starting material of CV-8972 was characterized using X-ray powder diffraction (XRPD), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and polarized light microscopy (PLM).
FIG. 4 is an )(RFD diffractogram of the CV-8972 starting material. The XRPD
results suggested high crystallinity of the starting material. Comparison of the XRPD
of the starting material with previously known polymorphs indicated that it is Form A.
FIG. 5 shows TGA and DSC thermograms of the CV-8972 starting material. TGA
thermogram is shown in green, and DSC thermogram is shown in blue. As shown by the TGA
and DSC data, about 3.46% weight loss was observed up to 150 C before decomposition. DSC
showed a small endotherm at 85.3 C (peak) and a possible melting endotherm at 214.6 C
(onset), followed by decomposition. and a melting point at 131.7 C (peak) was observed.
FIG. 6 shows )(RFD diffractograms of various forms of CV-8972. CV-8972 starting material is shown in blue; CV-8972 following incubation at 90 C for 8 hours is shown in red;
and CV-8972 following incubation at 65 C in a vacuum for 2 hours is shown in purple. To see if the small DSC endotherm at 85.3 C corresponds to polymorphic phase transition or dehydration, )(RFD was performed on Form A after storing it in an oven at 90 C for 8 hours. The data showed that the Form A converts to Form E.
FIG. 7 is a polarized microscopic image of CV-8972 starting material. Very platy "mica-like" morphology of the crystals was observed by PLM.
FIG. 8 is a dynamic vapor sorption isotherm plot. Cycle sorption is shown in red; cycle 1 desorption is shown in blue; and cycle 2 sorption is shown in green. DVS
results showed that water uptake of CV-8972 is <0.2% at 25 C and 80% relative humidity (RH) indicated that starting material was non hygroscopic. However, there is a drastic increase in the mass change beyond 80% RH, which indicates there could be deliquescence.
FIG. 9 shows XRPD diffractograms of CV-8972 before and after dynamic vapor sorption. Pre-DVS data is shown in red; and post-DVS data is shown in blue.
The XRPD of the .. sample after DVS indicated weak crystalline peaks but was mostly similar to the starting material.

FIG. 10 shows XRF'D diffractograms of CV-8972 in its dehydrated and rehydrated forms.
Data from starting material is shown in blue; data following incubation for 2 hours in vacuum oven are shown in red; and data from heated material that was exposed to ambient relative humidity is shown in green. To monitor Form A in its dehydrated state, it was placed in a vacuum oven at 65 C for 2 hours followed by its 'MD analysis. The XRPD results showed that this process created a new anhydrous form of the material and assigned as Form E. Rehydration of Form E when exposed to ambient RH resulted in its partial conversion to Form A.
X-ray powder diffraction data has been challenging to interpret due to the extreme preferred orientation, which results in large variations in the peak intensities from one sample preparation to the next. To minimize this effect, single crystal X-ray diffraction was used to acquire the crystallographic structure, and the X-ray powder diffraction that should be observed in an ideal sample that is absent of preferred orientation was calculated.
Polymorph/single crystal screening Starting with Form A, polymorph screening experiments were set up under 34 conditions using methods of slurry conversion, liquid vapor diffusion, slow evaporation, and slow cooling.
The approximate solubility of starting material was determined at room temperature (RT).
Accurately weighed samples of approximately 2 mg weight were added into a 3-mL
glass vial.
Solvents were then added step wise (50/50/200/700 L) into the vials until the solids were dissolved or a total volume of 1 mL was reached. The solubility of the starting material in various solvents is shown in Table 1.
Table 1. Approximate solubility of starting material (6010242-01-A) at RT
Experiment ID Solvent (v:v) Solubility (mg/mL) 6010242-02-Al n-Heptane S<1.9 6010242-02-A2 ACN S<1.5 6010242-02-A3 MIBK S<2.0 6010242-02-A4 Et0Ac S<1.8 6010242-02-A5 THF S<2.2 6010242-02-A6 Et0H S<1.7 6010242-02-A7 Acetone S<2.0 6010242-02-A8 MEK S<2.0 Experiment ID Solvent (v:v) Solubility (mg/mL) 6010242-02-A9 IPA S<2.3 6010242-02-A10 CHCI3 S<1.8 6010242-02-All IPAc S<1.7 6010242-02-Al2 1,4-Dioxane S<1.7 6010242-02-A13 CPME S<1.5 6010242-02-A14 DCM S<2.2 6010242-02-A15 Toluene S<2.3 6010242-02-A16 DMSO 5.0<S<15 6010242-02-A17 DMF 1.8<S<6.0 6010242-02-A18 NMP 6.7<S<20 6010242-02-A19 H20 S>44.0 6010242-02-A20 Me0H S>46.0 Results from solubility analysis were used to guide the solvent selection in polymorph screening. Polymorph screening experiments were performed using different crystallization or solid transition methods. Polymorph screening experiments are summarized in Table 2.
Table 2, Method No. of Experiments Crystal Type Liquid vapor diffusion 24 Form A, B, C, D, and E
Slow evaporation 2 Gel Slow cooling 2 No precipitation Slurry conversion 6 Form A
Total 34 Form A, B, C, D, and E
FIG. 11 shows XRF'D diffractograms of various polymorphs of CV-8972. Form A is shown in blue; Form B is shown in green; a mixture of Forms A and C is shown in navy; Form D
is shown in orange; and Form E is shown in purple.
The various crystal forms of CV-8972 are summarized in Table 3.

Table 3.
Crystal Form Method of obtaining Form Identification Form A Starting material Monohydrate*
Form B Liquid vapor diffusion of MTBE
Hydrate of unknown in Me0H stoichiometry#
Form C Multiple methods as listed below Solvate/hydrate (mixed with Form A) Form D Liquid vapor diffusion of IPA in Anhydrate*
Me0H
Form E 65 C Vacuum for 2 hours Anhydrate *Single crystal structures for these forms are available and are provided as separate reports Information obtained from separate report Liquid vapor diffusion experiments were conducted in different solvent conditions.
Approximately 15-25 mg of starting material was dissolved in an appropriate solvent to obtain a clear solution in a 3-mL vial. This solution was then placed into a 20-mL vial with 3 mL of volatile solvents. The 20-mL vial was sealed with a cap and kept at RT
allowing enough time for organic vapor to interact with the solution. The precipitates were isolated for XRPD analysis.
Results from liquid vapor diffusion experiments are summarized in Table 4.
Table 4.
Experiment ID Solvent Anti-solvent Observation 6010242-03-Al H20 MEK Amorphous 6010242-03-A2 1,4-Dioxane Gel 6010242-03-A3 THF Form A + C
6010242-03-A4 Acetone Form A + C
6010242-03-A5 ACN Form A + C
6010242-03-A6 Et0H Form A + C
6010242-03-A7 IPA Clear Experiment ID Solvent Anti-solvent Observation 6010242-03-A8 Me0H MEK Form A + C
6010242-03-A9 MTBE Single crystal (Form B) 6010242-03-A10 THF Gel 6010242-03-All Acetone Gel 6010242-03-Al2 ACN Gel 6010242-03-A13 Et0H FormA+C
6010242-03-A14 IPA Single crystal (Form D) 6010242-03-A15 Et0Ac Amorphous solid 6010242-07-Al Me0H IPA Form E
6010242-07-A2 IPA Form D
6010242-07-A3 IPA Form D
6010242-07-A4 Toluene Form A + C
6010242-07-A5 Dioxane Small single crystal on the wall (Form A + C) 6010242-07-A6 MIBK Small single crystal on the wall (Form A + C) 6010242-04-Al H20 MTBE Gel 6010242-04-A2 H20 IPA Gel 6010242-04-A3 Me0H DCM Small single crystal on the wall (Form A + C) Slow evaporation experiments were performed under various conditions. Briefly, a saturated solution of starting material prepared in different solvents was added to a HPLC vial.
The visually clear solutions were covered by Parafilm with 5-10 pinholes and subjected to evaporation at RT. The solids were isolated for XRPD analysis. Results from slow evaporation experiments are summarized in Table 5.

Table 5.
Experiment ID Solvent (v:v) Solid Form 6010242-06-A1 Me0H White solid poor crystalline 6010242-06-A2 H20 Gel Slow cooling experiments were conducted in two different solvent systems.
About 10-15 mg of starting material was suspended in appropriate solvent in a 2-mL glass vial at RT. The suspension was then heated to 50 C, equilibrated for about two hours and filtered using a nylon membrane (pore size of 0.22 m). Each filtrate was slowly cooled down to 5 C
at a rate of 0.1 C/min. Results from slow cooling experiments are summarized in Table 6, Table 6.
Experiment ID Solvent (v:v) Solid Form 6010242-05-Al DMSO No precipitation 6010242-05-A2 NMP No precipitation Slurry conversion experiments were conducted at RT in different solvent systems.
Approximately 20 mg of starting material was suspended in 0.1 mL of solvent in HPLC vials.
After the suspension was stirred magnetically for 48 hours at RT, the remaining solids were isolated for XRPD analysis. Results from slurry conversion experiments are summarized in Table 7.
Table 7.
Experiment ID Solvent (v:v) Solid Form 6010242-15-Al Acetone Form A
6010242-15-A2 Acetone/H20 (aw=0.2, 941/59) Form A
6010242-15-A3 Acetone/H20 (aw=0.4, 857/143) Form A
6010242-15-A4 Acetone/H20 (aw=0.6, 726/274) Form A
6010242-15-A5 Acetone/H20 (aw=0.8, 492/508) Form A
6010242-15-A6 H20 Form A

Experiment ID Solvent (v:v) Solid Form 6010242-15-A7 Form D + E in acetone Form A
Conclusions The Form A was successfully characterized to understand its form behavior. A
comprehensive polymorph screening in 34 different conditions was performed.
Five polymorph of the CV-8972 were identified during the screening, including Form A, Form B, a mixture of Forms A + C, Form D, and Form E. Form D and E are anhydrous, Form A is a monohydrate, and Form B is a hydrate with unknown stoichiometry. Phase origin of Form C is not known since it was not obtained it in pure form; it always crystallized as mixture with Form A. Based on polymorph screening it is apparent that CV-8972 has a tendency to form multiple polymorphs.
Current studies have concluded that Form A is the best form for development of CV-8972 and is a stable monohydrate form, and is the most stable form under conditions of ambient temperature and humidity.
Instruments and Methods Starting material was used to analyze Form A and screen for other polymorphs.
XRF'D was performed with a Panalytical X'Pert3 Powder XRPD on a Si zero-background holder. The 20 position was calibrated against a Panalytical Si reference standard disc.
Instrumental parameters used for XPRD are listed in Table 8.
Table 8.
Parameters Reflection Mode X-Ray wavelength Cu, ka Ka1 (A): 1.540598, Ka2 (A): 1.544426, Ka2/Ka1 intensity ratio: 0.50 X-Ray tube setting 45 kV, 40 mA
Divergence slit Fixed 1/8 Scan mode Continuous Scan range 3-40 ( 2TH) Parameters Reflection Mode Scan step time [s] 18.87 Step size ( 2TH) 0.0131 Test Time 4 min 15 s TGA data was collected using a TA Discovery 550 TGA from TA Instrument. DSC
was performed using a TA Q2000 DSC from TA Instrument. DSC was calibrated with Indium reference standard and the TGA was calibrated using nickel reference standard.
Detailed parameters used for TGA and DSC are listed in Table 9.
Table 9.
Parameters TGA DSC
Method Ramp Ramp Sample pan Platinum, open Aluminum, crimped Temperature RT ¨ 300 C
Heating rate 10 C/min Purge gas N2 Polarized light microscopic (PLM) pictures were captured on a Nikon DS-Fi2 upright microscope at room temperature. Low viscosity microscope immersion oil (Resolve ) was used to disperse powder crystals.
Example 2 Summary To determine the crystal structure of CV-8972, a single monohydrate crystal was grown, and a suitable single crystal was used for a full crystal X-ray diffraction (SCXRD) data collection at 199 K. A crystal structure with a Ri value of 0.0303 (I>2G(I)) was obtained. The structure showed that this crystal form is a monohydrate, tri-HC1 salt.

Crystal Growth and SCXRD preparation Single crystals of C22H34C13N306 (CV-8972) were obtained via slow cooling:
163.2 mg starting material was weighed into a 2-mL glass vial, and 0.100 mL water was added to dissolve the solids at 50 C, then the solution was slowly cooled to 10 C over 12 hours before harvesting.
FIG. 12 is a PLM image of a batch of single crystals of C22H34C13N306 (CV-8972). Bar represents 100 p.m.
FIG. 13 shows PLM images of a crystal used for single-crystal diffractometer.
Bars represent 100 p.m. A thick needle was picked out and trimmed down to a size of 200 x 160 x 100 um uniform block. This sample was mounted on a 100 mm MiTeGen MicroLoopTm with low viscosity cryo-oil (MiTeGen LV Cryo0i1Tm).
FIG. 14 shows images of a crystal mounted on a 100 micro Mitegen loop on the diffractometer.
Single Crystal Structure Determination A total of 9576 frames were collected using Bruker Apex3 v2018-7.2. The total exposure time was 18 hours (exposure times were adjusted based on 20). The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using an orthorhombic unit cell yielded a total of 157237 reflections to a maximum 0 angle of 81.010 (0.78 A resolution), of which 5641 were independent (average redundancy 27.874, completeness = 99.8%, Rim = 4.41%, Rsig = 1.34%) and 5388(95.51%) were greater than 2a(F2).
The final cell constants of a = 7.8826(2) A, b = 12.4776(3) A, c = 52.3580(13) A, volume =
5149.7(2) A3, are based upon the refinement of the XYZ-centroids of 1406 reflections above 20 G(I) with 11.750 <20 < 100.6 . Data were corrected for absorption effects using the Multi-Scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.788. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.5340 and 0.7160.
The structure was solved and refined using the 01ex2 incorporating SEIELXTL
Software Package using the orthorhombic space group Pbca, with Z = 8 for the formula unit, C22H34C13N306. One asymmetric unit contains one whole API molecule. The final anisotropic full-matrix least-squares refinement on F2 with 330 variables (0 restraints) converged at Ri =
3.03%, for the observed data and wR2 = 7.98% for all data. The goodness-of-fit was 1.041. The largest peak in the final difference electron density synthesis was 0.358 e-/A3 (0.81 A from Cli) and the largest hole was -0.438 e-/A3 (0.66 A from Cli). Most of the positions and thermal ellipsoids of hydrogens were treated as riding models (AFIX 23, AFIX 43, and AFIX 137 used).
However, the crucial hydrogen atoms involving hydrogen bonding and salt formation were refined freely without any constraints. On the basis of the final model, the calculated density was 1.400 g/cm3 and F(000), 2288 e-. Crystallographic parameters of the C22H34C13N306 crystal are summarized in Table 10.
Table 10.
Identification code 6010242 13 Chemical formula C22H34C13N306 Formula weight 542.87 g/mol Wavelength 1.54178 A
Temperature 199.0 K
Crystal size 0.10 x 0.16 x 0.20 mm Crystal habit colorless trimmed needle Crystal system orthorhombic Space group Pbca Unit cell dimensions a = 7.8826(2) A a = 900 b = 12.4776(3) A 13 = 90 c = 52.3580(13) A 7 = 90 Volume 5149.7(2) A3 Density (calculated) 1.400 g/cm3 Absorption coefficient( (CuKa)) 3.583 mm-1 F(000) 2288 Theta range for data collection 3.38 to 81.01 Index ranges -10<=h<=10, -15<=k<=15, -66<=1<=66 Reflections collected 157237 Independent reflections 5641 [R(int) = 0.0441]
Coverage of independent reflections 99.8%

Absorption correction Multi-Scan Max. and min. transmission 0.7160 and 0.5340 Structure solution technique direct methods Structure solution program XS (Sheldrick, 2008) Refinement method Full-matrix least-squares on F2 Refinement program XL (Sheldrick, 2008) Function minimized w(F02 _ Fc2)2 Data/restraints /parameters 5641/0/330 Goodness-of-fit on F2 1.041 A/amax 0.001 Final R indices 5388 data; I>2(I) Ri = 0.0303, wR2 = 0.0783 all data Ri = 0.0318, wR2 = 0.0798 Weighting scheme w=1/[a2(F02)+(0.0364P)2+2.762713]
where P=(F02+2F02)/3 Largest cliff, peak and hole 0.358 and -0.438 eA-3 R.M.S. deviation from mean 0.045 eA-3 FIG. 15 is an Ortep diagram of an asymmetric unit of the C22H34C13N306 crystal. The Ortep diagram of an asymmetric unit of the C22H34C13N306 crystal demonstrates that this API is a monohydrate tris-HC1 salt, as a ratio of 1:3:1 (API:HC1:H20) was observed.
FIG. 16 shows one unit cell of the C22H34C13N306 crystal.
FIG. 17 is a diagram of hydrogen bonds networks and counter-ion pairs in the C22H34C13N306 crystal. The diagram shows that the three hydrochloride molecules are deprotonated, whereas the three nitrogens are protonated. The water molecule serves as a hydrogen bond donor to bridging two chlorine anions. The crystallographic measurements of the hydrogen bonds and counter-ion pairs in the C22H34C13N306 crystal are summarized in Table 11.
Table 11.

D-H¨A d(DA)/A (D-I-1===A)/ d(D... A) ADHA) 06-H6A-C13#1 0.85(3) 2.37(3) 3.1997(18) 167.(2) 06-H6B-C12#2 0.91(3) 2.27(3) 3.1815(16) 176.(2) N2-H2-C11#3 0.932(18) 2.119(18) 3.0499(11) 177.1(16) 0.919(17) 2.127(18) 3.0462(11) 179.2(16) N3-H3-C13 0.95(2) 2.07(2) 2.9891(13) 163.9(19) Symmetry transformations used to generate equivalent atoms: #1: 2-X,0.5+Y,0.5-Z;#2:
0.5+X,+Y,0.5-Z;#3: 1+X,+Y,+Z;$4: 1.5-X,0.5+Y,+Z
The final cif file was checked with Platon using 01ex2 locally, only one level C alert was found (missing three reflections), together with eight level G alerts. An extensive data collection strategy was implemented to prevent this issue, and the completeness and redundancy of this dataset were 99.8% and 27.87, respectively.
FIG. 18 shows calculated and measured XRPD diagrams of the C22H34C13N306 crystal.
Calculated XRPD diffractogram is shown in red; and measured XRPD diffractogram is shown in blue. Powder x-ray diffraction of this batch was obtained and compared with a calculated pattern based on this crystal structure using Mercury. The experimental peak positions and intensities fit well with the calculated pattern.
Instruments and Methods The X-ray intensity data were measured at 199.0 K (controlled by Oxford Cryostream 800) on a Bruker Venture X-ray diffractometer. Incoatec Microfocus Source (41.S 3.0) monochromated Cu Ka radiation (X= 1.54178 A, voltage= 50 kV, current=1.1mA) was used as the x-ray source. The intensity data was collected by a Photon II detector.
Polarized light microscopic picture was captured on Nikon DS-Fi2 upright microscope at room temperature.
XRPD was performed with a Panalytical X'Pert3 Powder XRPD on a Si zero-background holder. The 20 position was calibrated against a Panalytical Si reference standard disc.
Example 3 Summary To determine the crystal structure of CV-8972, a single anhydrate crystal of was grown, and a suitable single crystal was used for a full Seal) data collection at 102 K. A
crystal structure with a Ri value of 0.0328 (I>2a(I)) was obtained. The structure showed that this crystal form is an anhydrous tri-HC1 salt.
Crystal Growth and SCXRD preparation Single crystals of anhydrous tri-HC1 salt of CV-8972 were obtained via liquid vapor diffusion of MTBE in Me0H solution. Briefly, a saturated solution of CV-8972 in Me0H was obtained at RT and filled into 2-mL glass vial, which was then kept inside a bigger 20 mL vial having 2 mL of MTBE, The vial was taken out when it showed presence of white crystalline material.
FIG. 19 shows PLM images of single anhydrous crystals from recrystallized CV-8972.
FIG. 20 is an image of a single anhydrous crystal from recrystallized CV-8972 mounted on a tip of a glass fiber. The colorless crystal was subsequently set up on the SCXRD instrument.
Single Crystal Structure Determination A colorless crystal was mounted on a tip of a glass fiber. The X-ray intensity data were measured at 102K temperature on a Bruker D8 Quest PHOTON 100 CMOS X-ray diffractometer system with Incoatec Microfocus Source (I S) monochromated Mo Ka radiation (X, = 0.71073 A, sealed tube) using omega/phi-scan technique. The data were collected in 1660 frames with 10 second exposure times. Crystallographic data: C22H3205N3C13: a = 6.9940(6) A, b = 10.5742(9) A, c = 17.5786(14) A, a= 78.252(2)0, ,8 = 82.823(2) 0, y = 82.476(2)0, V=
1255.37(18) A3, Z =
2, F.W. = 524.85, t = 0.403 mm-1, d = 1.389 g/cm3, F(000) = 552.
Crystal data and structure refinement for j l_a are provided in Table 12.
Table 12.
jl a Crystal data Chemical formula C22H32C13N305 Mr 524.85 Crystal system, space group Triclinic, Pi Temperature (K) 102 a, b, c (A) 6.9940 (6), 10.5742 (9), 17.5786 (14) ct, (3, y ( ) 78.252 (2), 82.823 (2), 82.476 (2) V (A3) 1255.37 (18) Radiation type Mo Ka (mm-i) 0.40 Crystal size (mm) 0.29 x 0.23 x 0.06 Data collection Diffractometer Bruker D8 Quest PHOTON 100 CMOS
Absorption correction Multi-scan BRUKER SADABS
Tmax 0.687, 0.747 No. of measured, independent 30843, 8732, 7553 and observed [I> 2G(/)]
reflections Rint 0.027 (sin 0/X)max (A-1) 0.746 Refinement R[F2 > 2G(F2)], .wR(F2), s 0.033, 0.098, 1.01 No. of reflections 8732 No. of parameters 310 No. of restraints 3 H-atom treatment H atoms treated by a mixture of independent and constrained refinement A)max, Amin (e k3) 0.55, -0.46 Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A2 x 103) for] 1_a are provided in Table 13. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor Table 13.
z U(eq) C1(1) 3641(1) 9477(1) 6048(1) 14(1) C1(2) 11992(1) 5170(1) 5985(1) 13(1) C1(3) 1821(1) 10077(1) 2138(1) 17(1) 0(1) 11846(1) 6620(1) 2868(1) 16(1) 0(2) 9860(1) 7793(1) 3643(1) 12(1) 0(3) 7371(1) 5399(1) 8524(1) 14(1) 0(4) 6912(1) 6708(1) 9782(1) 14(1) 0(5) 4066(1) 8571(1) 9907(1) 16(1) N(1) 5606(1) 8451(1) 2202(1) 15(1) N(2) 9414(1) 7581(1) 5446(1) 9(1) N(3) 6144(1) 6997(1) 6601(1) 9(1) C(1) 5518(2) 7647(1) 1711(1) 18(1) C(2) 6990(2) 6666(1) 1628(1) 18(1) C(3) 8550(2) 6526(1) 2067(1) 15(1) C(4) 8618(2) 7383(1) 2564(1) 12(1) C(5) 7105(2) 8356(1) 2629(1) 14(1) C(6) 10306(2) 7218(1) 3030(1) 12(1) C(7) 11386(2) 7722(1) 4138(1) 13(1) C(8) 10548(2) 8407(1) 4797(1) 11(1) C(9) 8935(2) 8244(1) 6132(1) 11(1) C(10) 7968(2) 7358(1) 6820(1) 11(1) C(11) 6595(2) 6347(1) 5908(1) 11(1) C(12) 7583(1) 7222(1) 5220(1) 10(1) C(13) 5051(2) 6149(1) 7265(1) 12(1) C(14) 4672(2) 6764(1) 7977(1) 11(1) C(15) 5894(1) 6385(1) 8580(1) 11(1) C(16) 5670(1) 7028(1) 9206(1) 11(1) C(17) 4153(2) 8022(1) 9262(1) 12(1) C(18) 2891(2) 8375(1) 8683(1) 13(1) C(19) 3177(2) 7754(1) 8045(1) 12(1) C(20) 7254(2) 4307(1) 9160(1) 17(1) C(21) 8819(2) 7087(1) 9516(1) 18(1) C(22) 2481(2) 9539(1) 10007(1) 21(1) Bond lengths [A] for j la are provided in Table 14.
Table 14.
0(1)-C(6) 1.2075(13) 0(2)-C(6) 1.3282(12) 0(2)-C(7) 1.4443(13) 0(3)-C(15) 1.3774(12) 0(3)-C(20) 1.4371(14) 0(4)-C(16) 1.3774(13) 0(4)-C(21) 1.4372(14) 0(5)-C(17) 1.3658(13) 0(5)-C(22) 1.4268(14) N(1)-H(1) 0.868(14) N(1)-C(1) 1.3404(15) N(1)-C(5) 1.3460(14) N(2)-H(2) 0.881(13) N(2)-C(8) 1.4972(13) N(2)-C(9) 1.4964(13) N(2)-C(12) 1.5025(13) N(3)-H(3) 0.868(13) N(3)-C(10) 1.4937(13) N(3)-C(11) 1.4993(13) N(3)-C(13) 1.5099(13) C(1)-C(2) 1.3793(17) C(2)-C(3) 1.3893(16) C(3)-C(4) 1.3898(15) C(4)-C(5) 1.3874(15) C(4)-C(6) 1.4909(15) C(7)-C(8) 1.5071(14) C(9)-C(10) 1.5162(14) C(11)-C(12) 1.5160(14) C(13)-C(14) 1.5052(14) C(14)-C(19) 1.3915(14) C(14)-C(15) 1.4062(14) C(15)-C(16) 1.3903(14) C(16)-C(17) 1.4014(14) C(17)-C(18) 1.3922(15) C(18)-C(19) 1.3926(15) Angles [deg] for j la are provided in Table 15.
Table 15.
C(6)-0(2)-C(7) 116.27(8) C(15)-0(3)-C(20) 113.71(8) C(16)-0(4)-C(21) 112.87(8) C(17)-0(5)-C(22) 116.45(9) H(1)-N(1)-C(1) 115.0(12) H(1)-N(1)-C(5) 122.2(12) C(1)-N(1)-C(5) 122.73(10) H(2)-N(2)-C(8) 108.6(11) H(2)-N(2)-C(9) 105.1(11) C(8)-N(2)-C(9) 110.24(8) H(2)-N(2)-C(12) 109.0(11) C(8)-N(2)-C(12) 114.11(8) C(9)-N(2)-C(12) 109.30(8) H(3)-N(3)-C(10) 107.1(11) H(3)-N(3)-C(11) 107.3(11) C(10)-N(3)-C(11) 109.71(8) H(3)-N(3)-C(13) 108.8(11) C(10)-N(3)-C(13) 113.17(8) C(11)-N(3)-C(13) 110.51(8) N(1)-C(1)-C(2) 120.40(11) C(1)-C(2)-C(3) 118.57(10) C(2)-C(3)-C(4) 119.88(10) C(5)-C(4)-C(3) 119.57(10) C(5)-C(4)-C(6) 121.37(9) C(3)-C(4)-C(6) 119.05(9) N(1)-C(5)-C(4) 118.85(10) 0(1)-C(6)-0(2) 125.57(10) 0(1)-C(6)-C(4) 123.74(10) 0(2)-C(6)-C(4) 110.67(9) 0(2)-C(7)-C(8) 107.00(8) N(2)-C(8)-C(7) 113.78(8) N(2)-C(9)-C(10) 110.57(8) N(3)-C(10)-C(9) 109.72(8) N(3)-C(11)-C(12) 111.10(8) N(2)-C(12)-C(11) 109.69(8) C(14)-C(13)-N(3) 110.97(8) C(19)-C(14)-C(15) 118.22(9) C(19)-C(14)-C(13) 121.58(9) C(15)-C(14)-C(13) 120.14(9) 0(3)-C(15)-C(16) 120.40(9) 0(3)-C(15)-C(14) 118.90(9) C(16)-C(15)-C(14) 120.65(9) 0(4)-C(16)-C(15) 121.32(9) 0(4)-C(16)-C(17) 118.62(9) C(15)-C(16)-C(17) 120.07(9) 0(5)-C(17)-C(18) 125.51(9) 0(5)-C(17)-C(16) 114.73(9) C(18)-C(17)-C(16) 119.75(9) C(17)-C(18)-C(19) 119.51(10) C(18)-C(19)-C(14) 121.71(10) Of the 8732 unique reflections collected to a maximum theta angle of 32.02 (0.67 A
resolution), 7553 were observed (I> 2 GO). The linear absorption coefficient for Mo Ka radiation is 0.403 mm-1. The data were integrated with the manufacturer's SAINT software and corrected for absorption effects using the Multi-Scan method (SADABS).
Subsequent solution and refinement were performed using the SHELXTL-2014 solution package operating on a Pentium computer. The structure was solved by direct method using SHELXTL-2014 Software Package. Non-hydrogen atomic scattering factors were taken from the literature tabulations. Non-hydrogen atoms were located from successive difference Fourier map calculations. In the final cycles of each refinement, all the non-hydrogen atoms were refined in anisotropic displacement parameters. Except for H(1), H(2), H(3) on N(1), N(2), N(3) atoms of the molecule that were located from difference Fourier map and refined with proper restraints, the rest of hydrogen atom positions were calculated and allowed to ride on the carbon to which they are bonded, assuming a C¨H bond length of m A (m = 0.990 for CH2 groups, m = 0.980 for CH3 groups, m = 0.950 for Ph-H groups). Hydrogen atom temperature factors were fixed at n (n = 1.2 for CH2, Ph-H groups, n = 1.5 for CH3) times the isotropic temperature factor of the C-atom to which they are bonded. The crystal system of compound is triclinic, space group P-1 (No. 2) and the final residual values based on 310 variable parameters and 7553 observed reflections (I> 2 (7(1)) are Ri = 0.0328, wR2 = 0.0926, and those for all unique reflections are Ri = 0.0408, w R2 = 0.0975. The goodness-of-fit indicator for all data is 1.014.
Peaks on the final difference map, ranging from 0.549 to -0.459 e/A3, are of no chemical significance. The efforts have been made to resolve as many alerts as possible generated by CheckCIF
program. The current highest alerts are at level G.
FIG. 21 is a thermal ellipsoid diagram of an asymmetric unit of the crystal. The diagram demonstrates that this form is an anhydrate, tris-HCl salt form.
FIG. 22 shows one unit cell of the C22H32C13N305 crystal.
FIG. 23 is a diagram of hydrogen bonds networks and counter-ion pairs in the C22H32C13N305 crystal.
FIG. 24 shows calculated and measured XRPD diagrams of the C22H34C13N306 crystal.
Calculated XRPD diffractogram is shown in red; and measured MUD diffractogram is shown in green.
The compound crystallizes in triclinic, space group P-1 (No. 2). The asymmetric unit contains one molecule in the form of cation/anion salt (an anhydrate tri-HCI
salt) with formula of C22H3205N3C13. There might be some intra-molecular H-bonding between N(1)-H(1)...C1(3) (with distance of 2.9634(10)), N(2)-H(2)...C1(2) (with distance of 2.9822(9)), N(3)-H(3)...C1(1) (with distance of 3.0120(9)). Structure solution, refinement and the calculation of derived results were performed using the SHELXTL-2014 package of computer programs. Neutral atom scattering factors were those of Cromer and Waber, and the real and imaginary anomalous dispersion corrections were those of Cromer.
Example 4 Introduction CV-8972 was synthesized according to Scheme 1.
Scheme 1:

,O, HN7N-i \\in \NnO
2134-trimethoxybenzaidehyde 2-(piperazin-1 -yi)ethan-1 -of \\)0 NaBH(0A0).3 Ac OH 0 . .
= _4* = = N =
2-MeTHF8 15 *(.; to RT
step 1 01881.4 Free Base ovi N Q
EDC, DMAP', DM
RT
=
step 2a CV8972 Free Base Ha =
corm, HC 'N) MEK,. 50 'T N,,,No" =
H20 Ha N' step 2b CV8912 MonohydrateHa NI+) H20, Me0H, MEK 0 N". 0 60 to RI N'OFL HO Ncr ,N os -step 3 HC

Step 1 is a reductive amination using 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-l-ol starting materials, with sodium triacetoxyborohydride (STAB) as the reductant, in the presence of catalytic acetic acid (AcOH), and 2-methyltetrahydrofuran (2-MeTHF) as solvent. After the reaction is completed, an aqueous workup, solvent exchange to MTBE, and recrystallization from MTBE/n-heptane forms the intermediate CV-8814 Free Base (CV8814 Free Base).
In step 2, CV-8814 Free Base (CV8814 Free Base) undergoes acid coupling with nicotinic acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and catalytic 4-(dimethylamino)pyridine (DMAP) in dichloromethane (DCM) solvent.
After aqueous workup, CV8972 Free Base is formed. Solvent exchange to 2-butanone (MEK) followed by addition into concentrated HC1 in MEK forms CV8972 Monohydrate intermediate.
The final step 3 is a form conversion in a mixture of water, methanol, and MEK
at 60 C
+ 5 C followed by a precipitation by the addition of MEK to obtain the desired form A of final product CV-8972 by )(RFD analysis.
Manufacturing details Manufacturing details are provided in Table 16.
Table 16.
Step # BOP#
Amount Started (Kg) Amount Produced (Kg) Yield (%) HPLC Purity (%) 1 2493-1903-00484 27.5 kg 34.0 kg 76.0%
100.0%
2 2479-1903-00489 28.8 kg 48.6 kg 96.4%
99.1%
3 2479-1904-00494 48.5 kg 41.7 kg 86.0 %
99.9%

Production details Step 1, formation of CV8814 Free Base (2493-1903-00487), was performed according to Scheme 2.
Scheme 2:
'µ'NO
-Li liN"'N, 0. ,=-=N 1 i +
,N.0õ,, ...c....=5 2,3,4-trimethoxybenzaidehyde 2-(piperazirt-111)ethan-l-ol \'µO
NaBH(0A03, MOH
2-MeTHF, 15 T to RT 0 /L .11, N
NCr -', L..õ '-e =
step I cvasu Free Base Production details for step 1 are provided in Table 17.
Table 17.
Identity Vendor / Grade / MW Equiv. Moles Expected Actual Quantity Quantity Used Name Catalog # g/mol Moles! moles Units Units mol-LR
2,3,4-Trimethoxy- Oakwood / 98% / 196.20 1.00 140.16 27.5 kg 27.5 kg benzaldehyde 078721; Chem-Impex / NA / 26868; Chem-Impex / NA / 26868 Identity Vendor / Grade / MW Equiv. Moles Expected Actual Quantity Quantity Used Name Catalog # g/mol Moles! moles Units Units mol-LR
1-(2-hydroxyethyppiperazine Aldrich / 98% / 130.19 1.1 154.18 20.1 kg 20.0 kg 2-Methyltetrahydrofuran (2- Aldrich 1>99.5% / N/A N/A N/A
309.5 kg 338.3 kg MeTHF) 155810 Plus As Needed Acetic Acid (AcOH) Aldrich /?99%1 N/A N/A N/A 1.40 kg 1.4101 kg Sodium Triacetoxy Oakwood / 95% / 211.94 2.00 280.32 59.4 kg Plus 60.3 kg Borohydride (STAB) 044864 As Needed Sodium Hydroxide solution, Aldrich / 50% in H20 40 6.09 853.57 68.3 kg 68.3 kg 50% in H20 (50% NaOH in /415413 H20) Sodium Chloride Aldrich / ACS / N/A N/A N/A 19.0 kg 19.0 kg (NaC1) S9888 Methyl tert-Butyl Ether Aldrich/ACS / N/A N/A N/A
417.3 Plus 552.1 kg (MTBE) 443808; Oakwood / As Needed Water Mediatech / WFI / 25- N/A N/A N/A 323.4 kg 323.4 kg 055-Xl; RMBI/ USP /

Heptane Aldrich / 99% / N/A N/A N/A 159.8 kg 162.1 kg H2198, Oakwood /
ACS / 044743; BDH /

Nitrogen Gas Airgas N/A N/A N/A Quantity Quantity (house system) >99% Sufficient Sufficient (QS) 1) Sodium Triacetoxy Borohydride (STAB; 60.3 kg; CHP Lot#: 181-190220) and 2-MeTHF
(189.2 kg; CHP Lot#: 234-190227) was charged to reactor R-401.
2) The contents of R-401 were agitated and the temperature was adjusted to 15 C + 5 C
3) 2,3,4-trimethoxybenzaldehyde (27.5 kg; CHP Lot#: 275-190311, 142-190212) and 2-MeTHIF (71.1 kg: CHP Lot#: 234-190227) was charged to reactor R-402.
4) Agitation of reactor R-402 was started.
5) 2-(piperazin-1-yl)ethan-1-ol (20.0 kg; CHP Lot#: 173-190220) and 2-MeTHF
(47.3 kg;
CHP Lot#: 234-190227) was charged to reactor R-402.
6) The contents of reactor R-402 were agitated for at least 5 minutes.
7) Acetic Acid (1.41 kg: CHP Lot#: 151-190214) was charged to reactor R-401 while keeping the temperature of the mixture below 25 C
8) Tmax = 14.4 C
9) The contents of reactor R-402 were transferred over 1 h 19 min while keeping the temperature of the mixture below 25 C.
10) Tmax = 29.2 C (the temperature went out of range during the addition) 11) The reaction was approved to proceed forward 12) The temperature of the contents of R-401 were adjusted to 20 C 5 C
and agitated for at least 6 hours at 20 C + 5 C.
13) The contents of R-401 were sampled after approximately 19 hours.
14) Analysis of the sample by QC indicated no peak of 2,3,4-trimethoxybenzaldehyde was detected, (specification < 1.5 area %) 15) The temperature of the contents of R-401 were adjusted to 15 C + 5 C

16) Water (247.5 kg; CHP Lot#: 232-190227) was charged to R-401 while keeping the temperature below 25 C.

17) Tmax = 14.6 C

18) The temperature of the contents of R-401 was adjusted to 20 C + 5 C and the contents were agitated for 30 minutes.

19) The contents of R-401 were allowed to settle for 30 minutes.

20) Phase cut was performed with the aqueous layer being transferred to R-402.

21) MTBE (203.8 kg; CHP Lot#: 207-190222) was charged to R-402.

22) The temperature of the contents of R-402 was adjusted to 0 C + 5 C.

23) 50% NaOH (68.3 kg; CHIP Lot#: 145-190213, 150-190214) was charged to R-402 while maintaining a temperature below 25 C.

24) Tmax = 11.5 C

25) After complete addition, the temperature of the contents of R-402 was adjusted to 20 C +
5 C.

26) The contents in R-402 were agitated for at least 30 min, followed by allowing the contents to settle for at least 30 min.

27) A phase cut was performed with the aqueous layer being transferred to reactor R-401 and the organic layer remaining in reactor R-402.

28) MTBE (61.0 kg; CHP Lot#: 207-190222) was charged to R-401.

29) The temperature of the contents of R-401 was adjusted to 20 C + 5 C.

30) The contents in R-401 were agitated for at least 15 min, followed by allowing the contents to settle for at least 15 min.

31) A phase cut was performed with the aqueous layer being transferred to a drum and the organic later remaining in reactor R-401.

32) FIO pH check of drummed aqueous layer pH = 13.20

33) The contents in R-402 were transferred to R-401.

34) 20% NaCl solution (94.4 kg; NaCl: 19.0 kg, CHIP Lot#: 156-190214; Water (75.9 kg;
CUP Lot#: 232-190227) was charged to R-401, agitated for at least 15 minutes and allowed to settle for at least 30 minutes.

35) A phase cut was performed with the aqueous layer being transferred to a drum.

36) The solution in R-401 was distilled under reduced pressure while maintaining a temperature <45 C to approximately ¨55 L total volume.

37) MTBE (61.1 kg; CHIP Lot#: 207-190222) was charged to R-401.

38) The contents in R-401 were distilled under reduced pressure while maintaining a temperature <45 C to approximately ¨82 L total volume.

39) MTBE (61.1 kg; CHIP Lot#: 207-190222) was charged to R-401.

40) The contents in R-101 were distilled under reduced pressure while maintaining a temperature <45 C to approximately ¨82 L total volume.

41) The contents of R-401 were sampled (IPC sample: 2493-1903-00484-85-01) to check the water content of the solution by KF analysis.

42) KF = 1.6% (specification < 0.5%)

43) MTBE (61.1 kg; CHP Lot#: 207-190222) was charged to R-401.

44) The contents in R-101 were distilled under reduced pressure while maintaining a temperature <45 C to approximately ¨82 L total volume.

45) The contents of R-401 were sampled (IPC sample: 2493-1903-00484-88-01) to check the water content of the solution by KF analysis.

46) KF = 0.8% (specification < 0.5%)

47) MTBE (61.1 kg; CHP Lot#: 207-190222) was charged to R-401.

48) The contents in R-101 were distilled under reduced pressure while maintaining a temperature <45 C to approximately ¨82 L total volume.

49) The contents of R-401 were sampled (IPC sample: 2493-1903-00484-91-01) to check the water content of the solution by KF analysis.

50) KF = 0.4% (specification < 0.5%)

51) MTBE (30.9 kg; CHP Lot#: 207-190222) was charged to R-401.

52) The temperature of the contents of R-401 was adjusted to 40 C + 5 C.

53) Heptane (56.3 kg; CHP Lot#: 233-190227) was charged over 8 min to R-401 while maintaining the temperature at 40 C 5 C.

54) = 38. PC

55) A FIO sample (FIO sample: 2493-1903-00484-100-01) was taken to observe the ratio of MTBE : Heptane of the contents in R-401. The ratio was 1.5 : 6Ø

56) The temperature of the contents of R-401 were adjusted to 28 C + 5 C
(Target 26 C to 29 C ) over at least 30 min and agitated at that temperature for at least 30 min.

57) Solid formation was observed.

58) The temperature of the contents of R-401 were adjusted to 30 C 3 C and agitated for at least 30 min.

59) Heptane (56.4 kg; CHP Lot#: 233-190227) was charged over 24 min to R-401 while maintaining the temperature at 30 C + 5 C.

60) Tinin = 30.2 C.

61) The temperature of the contents of R-401 were adjusted to 30 C 3 C
and agitated for at least 20 min.

62) The temperature of the contents of R-401 were adjusted to 20 C + 5 C
over at least 30 min and agitated for at least 20 min.

63) The temperature of the contents of R-401 were adjusted to 5 C + 5 C
over at least 30 min and agitated for at least 30 min.

64) The solid was collected on Filter-FD-400.

65) The contents of Filter-FD-400 were washed with cold heptane (49.4 kg;
CHP Lot#: 233-190227).

66) The contents of Filter-FD-400 were dried under vacuum at <25 C with a stream of N2 for at least 16 hours.

67) An IPC sample (IPC sample: 2493-1903-00484-122-01) was submitted to QC
for LOD.
= LOD = 0.20 % (specification < 0.5 %)

68) The product CV-8814 Free Base (CV8814 Free Base) was double bagged, goose necked, and weighed.

69) Analysis of dried material (IPC sample: 2493-1903-00484-122-01):
= Appearance: White to off white solid = Weight: 34.0 kg (78.0 % yield) = HPLC Purity = 100.0 %
= 1H NMR: conforms to structure

70) AS kg portion of CV-8814 Free Base (CV8814 Free Base) was removed from the bulk material double bagged, goose necked, and set aside for release under the Lot#

00484.
Step 2, formation of CV8972 Monohydrate (2479-1903-00489), was performed according to Scheme 3.
Scheme 3:

:
s'N = :
1r, = ,ez MC, MAP. MM
C'VW4 Free mizso stw: PA
õ -$
NO
õ0 01,,,,e,", ..") 0 ..,,- -y -...., tsi N.VA) =Nµsee'\\D'An $
Nr õ cvfasn Fill* elamo N'O
s.:n kJ J1CH
am. RC ,.-= ,...,ii,..,, .,---. Q
NoAN, Ap Pt W12 Monohydnite HO
Production details for steps 2a and 2b are provided in Table 18.
Table 18.
Identity Vendor / Grade / MW Equiv. Moles Expected Actual Quantity Quantity Used Name Catalog # g/mol Moles / moles Units Units mol-LR
CV8814 Free Base (IMB- CHP / NA / CHP Lot 310.39 1.00 92.79 28.8 kg 28.8 kg 1028814) #

>
Nicotinic Acid Aldrich /98% / 123.11 1.5 139.19 17.1 kg 17 1 kg N4126; Alfa Aesar/
99% / A12683 Identity Vendor! Grade! MW Equiv. Moles Expected Actual Quantity Quantity Used Name Catalog # g/mol Moles / moles Units Units mol-LR
CV8814 Free Base (IMB- CHP / NA / CHP Lot 310.39 1,00 92.79 28.8 kg 28,8 kg 1028814) >
Nicotinic Acid Aldrich /98% / 123.11 1.5 139.19 17.1 kg 17.1 kg N4126; Alfa Aesar/
99% / A12683 Dichloromethane (DCM) Aldrich / ACS / N/A N/A N/A 536.2 kg .. 533.4 kg EDC Oakwood / 99% / 191.71 1.5 139.19 26.7 kg 26.7 kg 024810; Chem-Impex / >99% / 00050 4-(Dimethylamino)pyridine Aldrich / >99% / 122.17 0.15 13.92 1.70 kg 1.70 kg (DMAP) 107700 Hydrochloric Acid (Conc Avantor / ACS / 36.46 3.3 306.21 30.2 kg 30.2 kg HC1) 2612-X' Sodium Bicarbonate Aldrich / ACS / N/A N/A N/A 4,0 kg 4.00 kg (NaHCO3) S6014 Water Mediatech / WFI / N/A N/A N/A 140.9 kg .. 140.4 kg 25-055-X'; RMBI/
USP /

Methyl Ethyl Ketone Oakwood / 99.9% / N/A N/A N/A 858.0 kg 857.8 kg (MEK) 075238 Nitrogen Gas Airgas N/A N/A N/A Quantity Quantity (house system) >99% Sufficient Sufficient (QS) 1) Nicotinic Acid (17.1 kg, CHP Lot# 201-190222) and DCM (153.0 kg, CHP
Lot# 328-190326) were charged to reactor R-401.
2) The contents of R-401 was agitated and the temperature was adjusted to 15 5 C.
3) CV8814 Free Base (28.8 kg, CHIP Lot# 2493-1903-00484), EDC (26.7 kg, CHIP Lot#
147-190213), DMAP (1.70 kg, CHIP Lot# 152-190214), and DCM (306.6 kg, CHP Lot#

190326) were charged to reactor R-402.

4) The contents of the R-402 were agitated for at least 20 minutes.
5) The contents of R-402 were transferred to R-401 over at least 30 minutes while keeping the temperature below 25 C.
6) Tmax = 20.0 C
7) The temperature of the contents of R-401were adjusted to 20 + 5 C and was agitated for at least 16 hours.
8) The contents of R-401 were sampled after approximately 16 hours.
9) Analysis of the sample by QC indicated 0 % (0.05%) of CV-8814 Free Base (CV8814 Free Base) with respect to CV8972 was detected (Specification: < 1% CV8814 Free Base).
10) The contents of the R-401 were adjusted to 10 + 5 C.
11) Water (29.2 kg, CHP Lot# 329-190326) was slowly added while keeping the temperature below 25 C.
12) Tmax = 12.3 C
13) The temperature of the contents of R-401 was adjusted to 20 + 5 C, agitated for at least 15 min and allowed to settle for at least 15 min.
14) Phases were separated.
15) The lower organic layer containing product was transferred to reactor R-402. The aqueous layer was sent to a drum.
16) Water (29.0 kg, CHP Lot# 329-190326) was charged to the reactor.
17) The biphasic mixture was agitated for 15 min and allowed to settle for 15 min.
18) Phases were separated.
19) The organic layer containing product was transferred to reactor R-401.
The aqueous layer was sent to a drum.
20) 8% NaHCO3 aqueous solution (Sodium Bicarbonate, 4.0 kg, CHP Lot# 192-190221;
Water, 53.2 kg, CHP Lot# 329-190326) was added to the reactor.
21) The mixture was agitated for at least 15 min and allowed to settle for at least 15 min.
22) Phases were separated.
23) The lower organic layer containing product was transferred to reactor R-402. The aqueous layer was sent to a drum.
24) Water (29.0 kg, CHP Lot# 329-190326) was added to the reactor.
25) The mixture was agitated for at least 15 min and allowed to settle for at least 15 min.

26) R-401 was cleaned with Water (17.6 kg, CHP Lot# 329-190326) and 1ViEK
(5.9 kg, CHP
Lot# 330-190326) and dried with a stream of N2.
27) Phases were separated.
28) The lower organic layer containing product was transferred to reactor R-401. The aqueous layer was sent to a drum.
29) The contents of R-401 were concentrated under reduced pressure to approx. 72 L keeping the temperature below 45 C.
30) Tmax = 32.0 C
31) MEK (139.0 kg, CHP Lot# 330-190326) was charged to R-401.
32) The contents of R-401 were concentrated under reduced pressure to approx. 72 L keeping the temperature below 45 C.
33) Tmax = 32.0 C
34) MEK (139.1 kg, CHP Lot# 330-190326) was charged to R-401.
35) The contents of R-401 were concentrated under reduced pressure to approx. 72 L keeping the temperature below 45 C.
36) Tmax = 29.2 C.
37) FIO 1H NMR to determine the DCM : MEK ratio was taken. DCM : MEK = 1 :
214.9 38) MEK (185.5 kg, CHP Lot# 330-190326) was charged to R-401.
39) MEK (208.7 kg, CHP Lot# 330-190326) and conc. HC1 (30.2 kg, CHP Lot#
274-190311) were charged to a cleaned R-402.
40) The temperature of the contents of reactor was adjusted to 25 + 5 C.
41) The contents of R-401 were transferred to R-402 over approx. 1 hour while maintaining a temperature below 35 C.
42) Tmax = 27.2 C
43) The temperature of the contents of R-402 was heated to 50 + 5 C and was agitated for at least 1 hour.
44) The temperature of the contents of the reactor was cooled to 20 + 5 C
over 2 hours.
45) The contents of the reactor were agitated at 20 + 5 C for 15 hours.
46) The solid was filtered.
47) The filter cake was rinsed with MEK (58.0 kg, CHP Lot# 330-190326).
48) The filter cake was rinsed with MEK (58.0 kg, CHP Lot# 330-190326).

49) The wet cake was dried in tray dryer 20 ¨ 25 C without nitrogen bleed for at least 16 hours.
50) An IPC sample (IPC sample: 2479-1903-00489-87-01) was submitted to QC
for KF.
= Water content (Specification: < 4% by cKF): 3.3%
51) The product CV8972 Monohydrate was doubled bagged, goose necked, and weighed.
52) Analysis of the dried material (IPC sample: 2479-1903-00489-87-01):
Appearance: White to off-white solid = Weight: 48.6 kg (96.4% yield) = 1H NMR: conforms to structure = HPLC purity (area %): 99.1%
= FIO Residual Solvents GC Analysis:
2-MeTHF: No Peak DCM: No Peak MTBE: No Peak Heptane: No Peak MEK: 343 ppm Acetic Acid: 874 ppm Step 3, formation of CV-8972 (2479-1904-00494), was performed according to Scheme 4.
Scheme 4:
N., HCI
0 HP, Me0H, MEK
I
w 0 1120 HO :k e CV8972 Monohydrate HC I step 3 \O

, , 0 H20 --Hcir 0 HCr Production details for step 3 are provided in Table 19.
Table 19.
Identity Vendor! Grade / MW Equiv. Moles Expected Actual Quantity Quantity Used Name Catalog # g/mol Moles / moles Units Units mol-LR
CV8972 CHIP / NA / CHP Lot 2479- 542.88 1 89.34 48.5 kg 48.5 kg monohydrate 1903-00489 Methanol Aldrich / ACS / 179337; N/A N/A N/A 230.5 kg 230.5 kg Pharmco / WORLD /
339WORLD-X'; BDH / ACS /

Methyl Ethyl Oakwood / 99.9% / 075238 N/A N/A N/A
1147.8 kg 1149.4 kg Ketone (MEK) Water Mediatech / WEI / 25-055-X1; N/A N/A N/A 72.8 kg 72,5 kg Quantity Nitrogen Gas Airgas Quantity N/A N/A N/A Sufficient (house system) 99% (QS) Sufficient 1) CV8972 monohydrate (48.5 kg, CHP Lot# 2479-1903-00489), Water (48.5 kg, CHP Lot#
329-190326), Methanol (19.2 kg, CHP Lot# 379-190404), and MEK (39.0 kg, CHP
Lot# 330-190326) were charged respectively to a reactor R-402.

2) The contents of the R-402 was adjusted to 20 C + 5 C and agitated until a solution was obtained.
3) The contents of R-402 were transferred to R-401 through a 0.45 micron in-line filter.
4) Water (24.0 kg, CHP Lot# 329-190326) and Methanol (19.2 kg, CHP Lot# 379-190404) were charged to R-402 and transferred to R-401 through a 0.45 micron in-line filter.
5) Methanol (192.1 kg, CHP Lot# 379-190404) was charged to R-401 through a 0.45 micron in-line filter.
6) The temperature of the contents of R-401 was adjusted to 60 + 5 C.
7) MEK (899.6 kg, CHP Lot#330-190326; 380-190404) was charged to R-401 through a 0.45 micron in-line filter over approx. 2 hours while maintaining a temperature of 60 + 5 C.
8) The contents of R-401 were agitated at 60 + 5 C for at least 4 hours.
9) The temperature of R-401 was adjusted to 20 5 C over at least 3 hours.
10) The contents of R-401 were agitated at 20 + 5 C for approx. 9 hours.
11) The contents of R-401 were sent to a filter.
12) The filter cake was rinsed with MEK (105.4 kg, CHP Lot # 380-190404).
13) The filter cake was rinsed with MEK (105.4 kg, CHP Lot# 380-190404).
14) The wet cake were dried on filter with vacuum for at least 30 minutes.
15) The wet cake was packaged into a filer dryer and dried under reduced pressure at < 30 C
for at least 12 hours.
16) An IPC sample (IPC sample: 2479-1904-00494-32-01) was submitted to QC
for KF and Residual Solvent GC.
= Water content (Specification: 2.8 ¨ 3.8% by cKF) = 3.5%
= Residual Solvent GC Analysis (Specification: Me0H < 3000 ppm; MEK < 5000 ppm) Me0H = 215 ppm; MEK = 185 ppm 17) The product CV-8972 was double bagged, goose necked, and weighed.
18) Analysis of the dried material (IPC sample: 2479-1904-00494-32-01) = Appearance: White to off-white solid = Weight = 41.7 kg (86.0% yield) = HPLC purity (area %) = 99.9%
Known Impurities:
Nicotinic Acid: No Peak DMAP: No Peak CV8814: 0.1%
2,3,4-Trimethoxy Benzaldehyde: No Peak Trimetazidine: No Peak CV-10099: No Peak CV-10046: No Peak = XRPD: Conforms to Form A
= Chloride Ion content: 19.4%
= 1H NMR: conforms to structure Conclusion The results provided above show that CV-8972 can be synthesized using Scheme 1. The reductive amination in step 1 using 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol starting materials, sodium triacetoxyborohydride (STAB) as the reductant, catalytic acetic acid (AcOH), and 2-methyltetrahydrofuran (2-MeTHF) gave a 78.0% yield of CV-8814 Free Base (CV8814 Free Base) with 100.0% purity by HPLC after aqueous workup, solvent exchange, and crystallization. A 5 kg portion of CV-8814 Free Base (CV8814 Free Base) was diverted from the synthesis for release. The step 2 coupling of CV8814 Free Base with nicotinic acid in the presence of EDC and catalytic DMAP in DCM went to complete conversion to CV8972 Free Base by HPLC IPC. Solvent exchange to MEK and addition into concentrated HC1 in MEK
afforded CV8972 Monohydrate in a 96.4% yield with 99.1% purity by HPLC. The final form conversion in step 3 was completed by heating CV8972 Monohydrate to 60 C + 5 C
in a mixture of water, methanol, and MEK and precipitating out with the addition of MEK. The white solid CV-8972 was obtained as form A confirmed by XRF'D analysis, in an 86.0%
yield with 99.9% purity by HPLC. The overall yield of the GlVIP synthesis of CV-8972 was 64.7%. The final amount of CV-8972 produced was 41.7 kg.
Incorporation by Reference References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure.
All such documents are hereby incorporated herein by reference in their entirety for all purposes.

Equivalents Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification, and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.

71

Claims (41)

Claims What is claimed is:

1. A crystal comprising a Form A polymorph of a compound of Formula (X):

N = --,, A.
LN----- \-----e' 0 -1, 1 (X).

2. The crystal of claim 1, wherein the crystal comprises a hydrochloride salt of the compound.

3. The crystal of claim 2, wherein the crystal comprises a hydrated form of the compound.

4. The crystal of claim 3, wherein the hydrated form of the compound is monohydrate.

5. The crystal of claim 1, wherein the crystal is substantially free of polymorphs of Form B, Form C, Form D, and Form E.

6. A pharmaceutical composition comprising a Form A polymorph of a compound of Formula (X):

Å.
OrH3 H1CO, I I
N
(X).

7. The composition of claim 6, wherein the composition comprises a hydrochloride salt of the compound.

8. The composition of claim 7, wherein the composition comprises a hydrated form of the compound.

9. The composition of claim 8, wherein the hydrated form of the compound is monohydrate.

10. The composition of claim 6, wherein the composition is substantially free of polymorphs of Form B, Form C, Form D, and Form E.

11. The composition of claim 6, wherein the composition is formulated for oral administration.

12. The composition of claim 6, wherein the composition is formulated as a single unit dosage.

13. The composition of claim 6, wherein the composition is formulated as divided dosages.

14. A method of treating a condition in a subject, the method comprising providing to a subject having, or at risk of developing, a condition a composition comprising a therapeutically effective amount of a Form A polymorph of a compound of Formula (X):

Å.
OrH3 H1CO, N
HICO
(X).

15. The method of claim 14, wherein the composition comprises a hydrochloride salt of the compound.

16. The method of claim 15, wherein the composition comprises a hydrated form of the compound.

17. The method of claim 16, wherein the hydrated form of the compound is monohydrate.

18. The method of claim 14, wherein the composition is provided orally.

19. The method of claim 14, wherein the composition is provided as a single unit dosage.

20. The method of claim 14, wherein the condition is selected from the group consisting of aneurysm, angina, atherosclerosis, cardiomyopathy, cerebral vascular disease, congenital heart disease, coronary artery disease, coronary heart disease, diabetic cardiomyopathy, heart attack, heart disease, heart failure, hypertension, ischemic heart disease, pericardial disease, peripheral arterial disease, rheumatic heart disease, stroke, transient ischemic attacks, and valvular heart di sease.

21. A method for preparing a compound of Formula (X):

N =
I
(X), the method comprising the steps of:
reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-o1 to produce a free base form of a compound of Formula (IX):

= = N
Fk CO' ."'b"":". = OH
(IX); and reacting the free base form of the compound of Formula (IX) with nicotinic acid to produce the compound of Formula (X), wherein the method does not comprise producing a salt form of the compound of Formula (IX).

22. The method of claim 21, wherein the step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-o1 comprises sodium triacetoxyborohydride.

23. The method of claim 21, wherein the step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-ypethan-1-o1 comprises acetic acid.

24. The method of claim 21, wherein the step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-o1 comprises 2-methyltetrahydrofuran.

25. The method of claim 21, wherein the step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-yl)ethan-1-ol is performed at from about 15 C to about 25 C.

26. The method of claim 21, wherein the step of reacting 2,3,4-trimethoxybenzaldehyde and 2-(piperazin-1-ypethan-1-o1 does not comprise dichloromethane.

27. The method of claim 21, wherein the step of reacting the free base form of the compound of Formula (IX) with nicotinic acid produces a free base form of the compound of Formula (X).

28. The method of claim 27, wherein the step of reacting the free base form of the compound of Formula (IX) with nicotinic acid compri se s 1 -ethy1-3 -(3 -dim ethyl ami nopropyl)carb odi i mi de .

29. The method of claim 27, wherein the step of reacting the free base form of the compound of Formula (IX) with nicotinic acid comprises 4-(dim ethyl amino)pyri dine.

30. The method of claim 27, wherein the step of reacting the free base form of the compound of Formula (IX) with nicotinic acid comprises dichloromethane.

31. The method of claim 27, wherein the step of reacting the free base form of the compound of Formula (IX) with nicotinic acid is performed at from about 20 C to about 25 C.

32. The method of claim 27, wherein the method further comprises converting the free base form of the compound of Formula (X) to a salt form of the compound of Formula (X).

33. The method of claim 32, wherein the salt form of the compound of Formula (X) is a HC1 salt.

34. The method of claim 32, wherein the salt form of the compound of Formula (X) is monohydrate.

35. The method of claim 32, wherein the step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) comprises HC1.

36. The method of claim 32, wherein the step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) comprises methyl ethyl ketone.

37. The method of claim 32, wherein the step of converting the free base form of the compound of Formula (X) to the salt form of the compound of Formula (X) is performed at about 50 C.

38. The method of claim 32, wherein the method further comprises converting the salt form of the compound of Formula (X) from a first crystal form to a second crystal form.

39. The method of claim 38, wherein the step of converting the salt form of the compound of Formula (X) from the first crystal form to the second crystal form comprises one selected from the group consisting of precipitating the salt form of the compound of Formula (X), changing the solvent of the salt form of the compound of Formula (X), and incubating the salt form of the compound of Formula (X), at about 60 C.

40. The method of claim 21, wherein the method does not comprise use of dioxane, ethylacetate, or potassium carbonate.

41. A method for preparing a compound of Formula (X):
. 0 li t_ II
(x), the method comprising the steps of:
reacting a compound of Formula (1):
'0 ( 1 ) with a compound of Formula (2):
HN
(2) to produce a free base form of a compound of Formula (IX):

H, CO
N
141.-)C0v -OH
(Do;
reacting the free base form of a compound of Formula (IX) with a compound of Formula (3):

'OH
(3) to produce a free base form of the compound of Formula (X); and converting the free base form of the compound of Formula (X) to a HC1 salt of the compound of Formula (X), wherein the method does not comprise producing a salt form of the compound of Formula (IX).